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B INTRODUCTION 
1 Background 
Cardiovascular diseases are still the most prominent cause of death in the 
Western world. The most important exponent of cardiovascular diseases is 
atherosclerosis (Libby, 2002). Cardiovascular risk factors such as genetic 
susceptibility, high blood pressure, smoking, or high cholesterol levels result in 
a chronic impairment of the endothelium which then triggers a cascade of 
events including the recruitment and transendothelial migration of circulating 
leukocytes. Cytokines and growth factors are released by these immune cells, 
generating a highly mitogenic environment. Vascular smooth muscle cells 
(VSMCs), a key player during the development of atherosclerosis, start 
migrating towards the atherosclerotic lesion. Subsequent proliferation and 
deposit of extracellular matrix components of the VSMCs thus contribute to the 
development of the so-called neo-intima (figure 1) (Dzau et al., 2002; Andres, 
2004). Another burden where VSMCs play a crucial role is restenosis. This 
phenomenon is amongst the most common complications (in up to 60% of all 
cases) after percutaneous transluminal coronary-angioplasty (PTCA), vascular 
surgery or cardiac surgery because of mechanical injury of the blood vessel 
(Greenberg et al., 2004). Restenosis is the result of progressive lumen 
narrowing caused by increased proliferation of VSMCs thereby reducing the 
benefit of percutaneous coronary intervention. 
Hence, new therapies preventing or at least reducing the rate of atherosclerosis 
or restenosis are main targets of research. Current researches encompass a 
variety of compounds such as statins, to lower blood cholesterol, or cytostatic 
drugs, to prevent narrowing of the vessel. Another field of research are natural 
compounds, in particular those which are widely used in folk medicine or have 
shown to diminish cardiovascular diseases in epidemiological studies. Detailed 
chemical investigation of the corresponding drugs or nutritions has shown that 
most of them are rich in polyphenolic constituents. 
B Introduction 2 
A
B
C
D
E
 
Figure 1. Processes in the response to injury hypothesis. A, normal vessel wall. Chronic 
endothelial impairment, hyperlipidemia, hypertension, and smoking leads to B, endothelial 
dysfunction (e.g. increased permeability, leukocyte adhesion). C, migration of smooth muscle 
cells from the media into the intima. D, Activation and transformation of monocytes into 
macrophages. After incorporation of lipid the macrophages become so-called foam cells 
eventually resulting in macroscopically apparent fatty streaks. E, intimal smooth muscle cells 
start proliferating and depositing extracellular matrix. This process together with foam cell-
derived lipid debris converts the fatty streaks into fibrofatty atheroma (Schoen F.J. and Cotran 
R.S., 1999). 
Two candidates worth being investigated are resveratrol 
(RV; trans-3,5,4'-trihydroxystilbene), and caffeic acid phenethyl ester 
(CAPE; trans-3-(3,4-dihydroxyphenyl)propenoic acid phenethyl ester). 
3 Aim of the work  
Resveratrol e.g. has been suggested to account for the so-called "French 
paradox", because it is a major component of red wine (Poussier et al., 2005) 
(for more details see chapter 4). And CAPE, the major constituent of propolis 
(see also section 5) has been shown to reduce restenosis in a rat model of 
vascular injury (Maffia et al., 2002). 
2 Aim of the work 
Objective of the present study was to investigate the effects of resveratrol (RV) 
and CAPE on VSMC hypertrophy and hyperplasia respectively. Primary rat 
aortic smooth muscle cells are widely used and accepted as a model in 
cardiovascular research. So, we used these cells to gain insight into the 
molecular signaling of VSMCs upon treatment with the above mentioned natural 
compounds. Since a recent study of our group has shown that RV suppresses 
angiotensin II induced hypertrophy in rat VSMCs (Haider et al., 2002), 
angiotensin II (Ang II, refer to chapter 6) and epidermal growth factor (EGF, see 
also section 7) were applied to investigate the underlying mechanism of 
resveratrol on inhibition of hypertrophy. Platelet-derived growth factor-BB 
(PDGF-BB) (a detailed description can be found in chapter 10) was used to 
examine the properties of CAPE on VSMC proliferation. 
The following two questions should be answered: 
1. Elucidation of signal transduction processes: what proteins are involved 
in the RV-mediated Akt inhibition in Ang II or EGF-activated VSMCs? 
2. Is CAPE capable of inhibiting PDGF-BB-induced proliferation of VSMCs? 
If so, what signaling pathways are involved? 
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3 Vascular smooth muscle cells (VSMCs) 
3.1 VSMCs in arterial narrowing 
In healthy arteries, VSMCs are fully differentiated and non-proliferating and 
belong to the media of the vessel wall (composition of the vessel see figure 1). 
However, if the inner arterial wall is damaged, VSMCs re-enter the cell cycle by 
means of cytokine and growth factor release from recruited platelets and 
impaired endothelial cells. This effect starts a few hours after injury of the vessel 
wall, e.g. after balloon angioplasty. Migration of the VSMCs into the intima 
begins at the fourth day, where they proliferate for another two weeks. At the 
end, extracellular matrix (ECM) is increasingly deposited which leads to fortified 
narrowing of the vessel (Braun-Dullaeus et al., 1998). Initially, this stenosis is 
compensated by progressive dilation of the vessel, but sustained ECM deposit 
finally obstructs blood flow and leads to the typical symptoms of atherosclerosis 
(Libby, 2002) such as angina pectoris or gangrene. 
3.2 Cultured VSMCs 
Culturing VSMCs leads to an altered phenotype compared to their in vivo 
counterparts. While in vivo smooth muscle cells show a contractile shape, 
cultured SMCs change to a more synthesizing phenotype, which is 
characterized by enhanced proliferation and ECM depositing (Shanahan and 
Weissberg, 1998). This behavior is similar to that of VSMCs during neointima 
formation and therefore a suitable model for cardiovascular research. 
5 Resveratrol (RV)  
4 Resveratrol (RV) 
4.1 Discovery, sources and biological function 
Resveratrol can be found in grapes, peanuts and a few other fruits and 
vegetables. It was first isolated from the roots of Japanese knotweed 
(Polygonum cuspidatum) by Nonomura et al. in 1963. This herb is used in Asian 
folk-medicine against suppurative dermatitis, gonorrhea and hyperlipidemia 
(NONOMURA et al., 1963). Major interest in resveratrol came up with its 
discovery in red wine in 1992 (Siemann and Creasy, 1992). Since it is present 
in grape berry skins but not in grape flesh, white wine contains only small 
amounts of resveratrol. Concentrations in fresh grape skin vary from 50 to 
100 mg/g (Soleas et al., 1997). Since resveratrol is a phytoalexin, this 
compound is produced in response to UV-irradiation, exposure to ozone or 
pathogen attack. Grapes (Vitis vinifera) synthesize resveratrol in response to 
fungal infections. Thus, it is more abundant in grapes grown in cooler, humid 
climates where fungal infections are more frequent. 
4.2 Features 
By its discovery in red wine 1992, resveratrol gained increasing interest and 
many of studies have been performed, revealing an increasing number of 
biological properties. The following passage will focus on the features of major 
interest for this study. 
4.2.1 Anti-inflammatory properties 
One important family of enzymes involved in inflammation are cyclooxygenases 
(COX). Resveratrol has been shown to interfere with COX, however alterations 
of COX gene expression and activity by resveratrol differ in diverse models 
(Jang et al., 1997; Chow et al., 2005). Anyhow, anti-inflammatory properties of 
resveratrol were confirmed in vivo, since carrageenan-induced paw edema was 
suppressed by resveratrol in both the acute and the chronic phase (Jang et al., 
1997). In addition to COX, inhibition of the 5-lipoxygenase and the 
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15-lipoxygenase pathway was also demonstrated in several models (Soleas et 
al., 2001). 
4.2.2 Cell cycle  
In several cell lines including VSMCs, resveratrol exhibits antimitogenic 
properties. Proliferation and DNA synthesis was shown to be inhibited dose-
dependently (Oak et al., 2005; Haider et al., 2003; Chao et al., 2005). Referring 
to this, in vitro experiments investigating enzyme activity of 
ribonucleotidreductase (Matsuoka et al., 2004; Fontecave et al., 1998) as well 
as DNA-polymerase α and δ (Locatelli et al., 2005), revealed that resveratrol 
acts as an inhibitor of these enzymes. Resveratrol showed various effects on 
other important cell cycle proteins such as the cyclins, p21Cip1 or the 
retinoblastoma protein (Rb) (Chow et al., 2005; Poussier et al., 2005; Haider et 
al., 2003; Adhami et al., 2001; Hsieh et al., 2002). 
4.2.3 Cardiovascular effects 
Resveratrol has been shown in several studies to prevent platelet aggregation 
(Delmas et al., 2005; Olas and Wachowicz, 2005). Furthermore, tumor necrosis 
factor α (TNF-α)-induced expression of the adhesion molecules ICAM-1 and 
VCAM-1 as well as adhesion of THP-1 monocytic cells to human umbilical vein 
endothelial cells has been demonstrated to be reduced by resveratrol (Ahn et 
al., 2000). It has been reported that resveratrol leads to an increase in eNOS 
activity, protein and mRNA expression (Wallerath et al., 2002). More recently, 
Kaga et al. recently provided evidence that resveratrol is capable of enhancing 
neo-vascularization in the infarcted rat myocardium (Kaga et al., 2005). 
4.2.4 Bioavailability 
To evaluate the positive effects of moderate wine consumption and to review 
the in vivo efficiency bioavailability studies have been performed. Some red 
wine polyphenols, including trans-resveratrol, have been shown to be highly 
absorbed but also rapidly and extensively metabolized through glucuronidation 
or sulfatation in the liver (Goldberg et al., 2003; Meng et al., 2004; Vitaglione et 
al., 2005). The half-life of RV is ~8-14 minutes for the unchanged molecule 
7 Caffeic acid phenethyl ester (CAPE)  
(Baur and Sinclair, 2006). On the other hand, Bertelli et al. suggested an 
accumulation of resveratrol in different organs after prolonged oral 
administration to rats (Bertelli et al., 1996), and Vitaglione et al. investigated 
absorption of resveratrol from moderate consumption of red wine (300-600 ml). 
They could show that resveratrol can actually be absorbed even after moderate 
wine consumption (Vitaglione et al., 2005). So far, the existing data on the 
bioavailability of resveratrol is contradictory and confusing. The various different 
settings within all the studies raise some doubts about the concentration that 
are achievable in vivo (Baur and Sinclair, 2006). Therefore, it is difficult to 
connect the well-known beneficial effects of RV obtained from in vivo or cell-
based studies to potential effects expected after ingestion of resveratrol-
containing foods. 
5 Caffeic acid phenethyl ester (CAPE) 
5.1 Discovery, source and biological function 
Caffeic acid phenethyl ester (CAPE) was first described by Grunberger et al. in 
1988 as the major active element of propolis (Grunberger et al., 1988), a 
resinous substance collected from honey bees. The name propolis is derived 
from the Greek syllables pro which means “in front of” and polis which means 
“city” and stands for a material to cover hive walls, fill gaps and embalm killed 
invaders, briefly a substance to defend the bee-hive. Propolis is an old remedy 
which has been used at least since 300 BC. Until now, over 180 compounds, 
mainly polyphenols, have been identified from propolis.  
5.2 Features 
CAPE was isolated from propolis in 1988 (Grunberger et al., 1988). The 
subsequent discovery of its preferential cytotoxicity on tumor cells was the 
matter for further studies, revealing numerous biological properties. Therefore 
this paragraph will give a short overview of distinct features of CAPE. 
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5.2.1 Antioxidative properties 
CAPE has shown its antioxidative activities in different biological systems and in 
vitro (Ozguner et al., 2005; Oktem et al., 2005; Hsu et al., 2005). The 
antioxidative activity of CAPE was first described by Sud’ina et al. (Sud'ina et 
al., 1993) showing that CAPE is an antioxidant which is also able to interfere 
with the arachidonic acid pathway via inhibition of 5-lipoxygenase (5-LOX) thus 
reducing inflammation. 
5.2.2 Anti-inflammatory and chemopreventive properties 
CAPE has been shown to inhibit 5-lipoxygenase (Sud'ina et al., 1993). 
Moreover several studies with CAPE demonstrate cyclooxygenase (COX) 
inhibition (Lee et al., 2004; Ye et al., 2004). Inhibition of the nuclear transcription 
factor κB (NF-κB) is the best investigated activity of CAPE (Natarajan et al., 
1996; Hishikawa et al., 2005; Lee et al., 2004; Ye et al., 2004). NF-κB is not 
only important in inflammation, as e.g. the cox2 promotor contains NF-κB 
binding sites (Lee et al., 2004) but it has been shown to be constitutively 
activated in several types of cancer cells (Ye et al., 2004). Therefore it is not 
surprising that several studies have shown that CAPE is able to induce 
apoptosis in different cancer cell lines (Orsolic et al., 2004; Chen et al., 2004). 
5.2.3 Cardiovascular effects 
Maffia et al. could give evidence that CAPE is able to reduce occurring 
restenosis after balloon angioplasty in a rat model (Maffia et al., 2002). Other 
studies demonstrated that CAPE causes relaxation of the phenylephrin or KCl 
pre-contracted rat thoracic aortic ring (Cicala et al., 2003), and that CAPE 
attenuates atherosclerosis development in apolipoprotein E-deficient mice 
(Hishikawa et al., 2005). Moreover CAPE was able to inhibit chlamydophila 
pneumoniae-induced ICAM-1 upregulation in human aortic endothelial cells 
(Vielma et al., 2003). 
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5.2.4 Effects on proliferation 
CAPE exhibits anti-proliferative properties in different cell types including 
vascular smooth muscle cells (Wang et al., 2005; Liao et al., 2003; Zheng et al., 
1995). It was shown to inhibit angiogenesis in chick embryo chorioallantoic 
membranes (Song et al., 2002). This result is consistent with findings showing 
CAPE to reduce the vascular endothelial growth factor (VEGF) production and 
expression of matrix metalloproteinase (MMP)-2 and -9 in CT26 cell culture 
(Liao et al., 2003). 
5.2.5 Bioavailability 
Until today only little is known on how effectively CAPE is absorbed after oral 
supplementation. However there are some recent studies where CAPE has 
been administered orally. Celli et al. developed and validated a new analytical 
method to determine CAPE in rat plasma and urine. They showed that CAPE is 
rapidly absorbed and excreted in urine both as unmodified molecule and as 
glucuronide conjugate although in a low amount compared to the administered 
dose (Celli et al., 2004). Effects of CAPE on the immune system in mice 
suggest an immunemodulatory capacity of CAPE when given orally (Park et al., 
2004; Orsolic et al., 2006). CAPE was shown to be capable of attenuating the 
development of atherosclerosis in ApoE null mice after oral application 
(Hishikawa et al., 2005). Up to now, the existing data on the bioavailability of 
CAPE is difficult to interpret. CAPE has been shown to be quickly absorbed but 
it is also rapidly metabolized and excreted. The existing animal studies, though, 
show that an oral intake of CAPE is associated with biological effects in vivo 
that can be demonstrated also in vitro. 
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6 Angiotensin II 
6.1 History 
More than 50 years ago, synthesis and pharmacologic properties of 
angiotensin II were described for the first time. For a long time angiotensin II 
was only regarded an important and potent vasoconstrictor. It was in the early 
1990s that pro-inflammatory and proliferative properties were found for 
angiotensin II. Since then rapid progress was made in the elucidation of the 
underlying mechanisms of these findings (Alexander and Dzau, 2000). 
6.2 Structure and metabolism 
Angiotensin II is an octapeptide hormone that can be produced systemically via 
the renal renin-angiotensin system as well as locally by the tissue renin-
angiotensin system (Touyz and Berry, 2002). 
6.2.1 The renin-angiotensin system: 
Angiotensinogen, a hepatic-derived α-globulin, is cleaved at the N-terminus by 
means of renal-derived renin. In the lungs, the resulting decapeptide 
angiotensin I is then converted into angiotensin II by action of the dipeptidyl 
carboxypeptidase angiotensin-converting enzyme (ACE). 
The latter step can also be catalyzed by several enzymes different from ACE, 
such as chymase, carboxypeptidase and cathepsin G. But although these 
enzymes are present in atherosclerotic lesions, the affinity of angiotensin I to 
ACE is higher, suggesting that angiotensin II generation in atherosclerotic 
vessels depends mainly on ACE (Schmidt-Ott et al., 2000). 
Angiotensin I can be transformed further to the heptapeptide angiotensin II (1-7) 
by tissue endopeptidases. Angiotensin II (1-7) seems to be a naturally occurring 
antagonist of angiotensin II actions (Touyz and Berry, 2002). 
Subsequent degradation of angiotensin II to angiotensin III and angiotensin IV is 
performed by aminopeptidases (Touyz and Berry, 2002). 
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6.2.2 The tissue angiotensin: 
Generation of angiotensin II is not limited to the renal renin-angiotensin system 
as all components are expressed in the vessel wall (Schmidt-Ott et al., 2000). 
Angiotensinogen mRNA was found in VSMCs of healthy arteries and it has 
been shown that the levels increased in both the media and the neointima after 
balloon angioplasty in rats (Rakugi et al., 1993). Renin mRNA and protein were 
detected predominantly in the media and here, too, the levels rose after balloon 
injury (Iwai et al., 1997). ACE seems to prevail in endothelial cells, but in 
atherosclerotic lesions it can be detected also in macrophages (Fukuhara et al., 
2000).  
Altogether, there is evidence that these tissue renin-angiotensin systems may 
play an important role in both local regulation of blood flow and pathogenesis of 
cardiovascular disease (Weiss et al., 2001; Touyz and Berry, 2002).  
6.3 Receptors 
Angiotensin II mediates its effects through G protein-coupled receptors 
(GPCRs). So far four receptors have been identified of which AT1 and AT2 play 
the most important role. The role of AT3 and AT4 has not been entirely 
elucidated yet (Touyz and Berry, 2002). 
Most vascular effects of angiotensin II are mediated via the AT1 receptor 
(AT1-R). This seven-transmembrane glycoprotein, composed of 359 amino 
acids, activates phospholipase C (PLC) via a heterotrimeric Gq protein (Touyz 
and Berry, 2002). The AT1-R is localized mainly in VSMCs, whereas levels in 
the adventitia are low and endothelial cells seem not to contain significant 
amounts (Allen et al., 2000; Zhuo et al., 1998). Interestingly, the density of 
AT1-R is increased in the media of damaged blood vessels compared to that of 
healthy animals (Yang et al., 1998). 
The AT2-R is a seven-transmembrane GPCR, too, but shares only little 
homology with the AT1-R (approx. 32%). It consists of 363 amino acids and is 
expressed predominantly in fetal tissues. After birth the levels decrease very 
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fast and are restricted to certain organs such as the brain, adrenal medulla, 
kidney, uterus, and ovary (Johren et al., 2004). Only 10% of the total 
angiotensin receptors in healthy vessels are of the AT2-type (Schmidt-Ott et al., 
2000) and are mainly localized in adventitia and endothelial cells, but not in 
VSMCs (Zhuo et al., 1998; Wang et al., 1998). There is evidence that levels of 
the AT2-R, in contrast to AT1-R, are not altered in atherosclerotic vessels (Yang 
et al., 1998). 
Until now, the main function of the AT2-R is believed to mediate antagonistic 
effects compared to that of the AT1-R (Allen et al., 2000). 
6.4 Physiology 
Angiotensin II causes VSMC contraction within seconds. This effect is mediated 
by activation of PLC-β1 via the Gq-coupled AT1-R and subsequent increase of 
intracellular Ca2+ levels (Touyz and Berry, 2002). Ca2+ associates with 
calmodulin, resulting in the activation of the myosin light chain kinase, a crucial 
requirement for contraction (Morano, 1992). The Ca2+-increase upon 
angiotensin II stimulation is biphasic. First, PLC-β1 hydrolyses 
4,5-phosphorylated phosphatidylinositol (PtdIns) generating inositol 
triphosphate (IP3) and diacylglycerol (DAG). Intracellular Ca2+ is mobilized by 
IP3 from the sarcoplasmic reticulum, leading to a rapid and transient increase in 
Ca2+ levels. The more sustained second wave results from transmembrane 
Ca2+ influx. In addition to IP3-mediated mobilization of intracellular Ca2+ and 
influx of extracellular Ca2+, tyrosine kinase-dependent increase of intracellular 
Ca2+ has been suggested (Touyz and Berry, 2002). 
DAG, the other second messenger generated by PLC, also contributes to 
vasoconstriction. Together with Ca2+ and phosphatidylserine, it activates protein 
kinase C (PKC), a serine/threonine kinase existing in several isoforms. PKC 
leads to activation of the Na+/H+ exchanger, thereby resulting in intracellular pH 
shift towards alkaline conditions. This alkalization has been shown to induce 
vasoconstriction by increasing intracellular Na+ and Ca2+ levels and sensitizing 
the contractile apparatus (Touyz and Berry, 2002). 
13 Angiotensin II  
Finally, angiotensin II regulates blood pressure and plasma volume by 
stimulation of renal Na+ and water resorption, aldosterone release, sympathetic 
nervous system and thirst response (Touyz and Berry, 2002). 
6.5 Pathophysiology 
The pathologic activities of angiotensin II resulting in atherosclerosis are not 
restricted to VSMCs but involve all components of the vessel wall. This chapter 
will first give a brief summary of angiotensin II actions in the vascular wall in 
general. Afterwards, the effects of angiotensin II in VSMC will be discussed in 
more detail. 
6.5.1 Angiotensin II and the vessel wall 
Over the last century, several theories have emerged to account for the 
development, progression, and complication of atherosclerosis. The lipid 
hypothesis proposed by Anitschkow and Chalatow in 1913 (Nil, 1913) attributed 
atherosclerosis to gradual lipid accumulation in the arterial wall. In the 
thrombogenic hypothesis, growth of atherosclerotic plaques results from 
gradual incorporation of luminal thrombi into the arterial wall (Weissberg and 
Rudd J, 2002). The response to injury hypothesis supports the notion of 
atherosclerosis as a protective response to various factors causing endothelial 
injury (Ross, 1999). Currently, inflammation is being recognized as pivotal in the 
pathogenesis of atherosclerosis (Tiong and Brieger, 2005). In experimental 
settings many features of atherosclerosis can be mimicked by angiotensin II. 
Furthermore, angiotensin II triggers both inflammation and oxidative stress 
(Weiss et al., 2001). 
The hormone is crucially involved in the generation of reactive oxygen species 
(ROS) in the vasculature. The most important source of ROS in the vessel is 
NAP(P)H oxidase (NOX). Other relevant sources are xanthine oxidase, 
lipoxygenases (LOX), and cytochrom P450 monooxygenase (Touyz and Berry, 
2002). Increased, angiotensin II-induced ROS generation contributes to 
endothelial dysfunction and oxidation of low-density lipoprotein (LDL). 
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Moreover, angiotensin II increases the expression of cell adhesion molecules 
on endothelial cells and VSMCs thereby enhancing leukocyte infiltration through 
the vessel wall (Schmidt-Ott et al., 2000). Last but not least, angiotensin II is 
capable of inducing apoptosis in endothelial cells. This may contribute to 
damage in the endothelial monolayer (Schmidt-Ott et al., 2000). 
6.5.2 Angiotensin II and VSMCs 
Effects on intracellular signaling 
Angiotensin II provokes plenty of actions by activation of AT1-Rs in VSMCs 
ranging from phosphorylation and activation of various kinases and 
phospholipases to transactivation of receptor tyrosine kinases (RTKs) (Touyz 
and Schiffrin, 2000). In the following paragraph the pathways important for this 
study are discussed. 
Effects on VSMC function 
Protein synthesis and cellular hypertrophy in cultured VSMCs is one effect of 
angiotensin II stimulation (Berk et al., 1989; Geisterfer et al., 1988). However, in 
the presence of other growth factors hyperplasia can be induced by 
angiotensin II. Additionally angiotensin II has been shown to provoke VSMC 
migration in transwell-culture chambers (Xi et al., 1999). 
Beside these direct effects, angiotensin II can act indirectly inducing the 
production of various growth factors, cyto- and chemokines, including 
macrophage chemoattractant protein 1 (MCP-1), interleukin 6 (IL 6), 
transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), 
insulin-like growth factor-1 (IGF-1), basic fibroblast growth factor (bFGF), and 
epidermal growth factor (EGF). All these molecules, except TGF-β which 
induces collagen synthesis, enhance VSMC proliferation and migration and 
augment inflammation (Schmidt-Ott et al., 2000). 
Furthermore, angiotensin II induces changes in extracellular matrix (ECM) 
composition. Non-proliferating, contractile VSMCs synthesize only little amounts 
of ECM. During vascular remodeling, VSMCs change their phenotype towards a 
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proliferative, synthesizing one, thereby increasing production of fibronectin, 
collagen and elastin. Interestingly, these changes in the extracellular 
environment promote proliferation and migration (Schmidt-Ott et al., 2000). 
7 Epidermal growth factor receptor (EGF-R) transactivation 
The EGF-R can be activated by direct ligand binding and by transactivation 
through other pathways, including those triggered by cytokine receptors, ion 
channels and GPCRs (Breitling and Hoeller, 2005). Transactivation of the 
EGF-R through the AT1-R has been suggested to be a pivotal step in 
angiotensin II signaling (Voisin et al., 2002; Wolf, 2005; Yang et al., 2005). To 
focus on signaling downstream of EGF-R transactivation in several experiments 
epidermal growth factor (EGF) was used to activate VSMCs. 
7.1 EGF-Receptors 
The EGF-receptor (EGF-R, also termed HER1/ErbB-1) was the first receptor 
tyrosine kinase (RTK) to be discovered in 1978 (Carpenter et al., 1978). It 
belongs to the EGF-R subfamily of RTKs.  
The EGF-R is a transmembrane glycoprotein consisting of 1186 amino acids. 
The intracellular domain can be subdivided into three domains: the 
juxtamembrane domain, which serves as a site for feedback attenuation by 
protein kinase C (PKC) and extracellular-signal regulated kinase 1/2 (Erk1/2). It 
is followed by the kinase domain which in turn is succeeded by the carboxy-
terminal tail that has autoinhibitory function by serving as an inhibitory substrate 
for the kinase domain. Autophosphorylation of the EGF-R is a prerequisite for 
kinase activation. The resulting phospho-sites serve as docking-sites for several 
signaling and scaffold molecules containing phospho-tyrosine binding domains 
(Dreux et al., 2005). Upon ligand binding to the extracellular domain, the 
conformation of the receptor is changed hence leading to the exposure of 
receptor-receptor interaction site. This results in the dimerization of two ligand-
occupied EGF-Rs. All EGF-R family members are capable of building dimers. 
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The dimerization facilitates intermolecular autophosphorylation resulting in full 
tyrosine kinase activity (Dreux et al., 2005). 
7.2 Transactivation by the AT1-Receptor 
EGF-R transactivation in VSMCs upon stimulation of the AT1-R has been 
shown to be essential for protein synthesis (Voisin et al., 2002). It has further 
been demonstrated to be linked to the activation of extracellular-signal 
regulated kinase 1/2 and p38 MAPK (Eguchi et al., 2001; Frank et al., 2001), 
the serine/threonine kinase Akt and p70 S6 kinase (p70S6K) (Eguchi et al., 
1999b). 
Due to the rapid phosphorylation of the EGF-R as well as a result of lack of 
EGF-R ligands in conditioned medium, transactivation of the EGF-R was 
believed to be mediated solely by intracellular events (Daub et al., 1997). 
Various pathway have been considered. It was shown that in VSMCs Ang II 
stimulation led to transactivation of the EGF-R and subsequently to its 
association with the adaptor proteins Shc and Grb2. This reaction was 
mimicked by using by a calcium ionophore and completely inhibited by an 
intracellular Ca2+ chelator (Eguchi et al., 1998). Proline-rich tyrosine kinase 2 
(Pyk 2), a calcium dependent tyrosine kinase, was demonstrated to be involved 
in the transactivation cascade. Ang II leads to phosphorylation of Pyk2 which in 
turn is able to activate EGF-R associated c-Src thereby causing transactivation 
(Eguchi et al., 1999a). The Ang II induced c-Src activation was shown to be 
crucially dependent on the generation of reactive oxygen species (ROS) (Ushio-
Fukai et al., 2001a). To summarize, concerning angiotensin II signaling in 
VSMCs, the tyrosine kinase c-Src, Ca2+-dependentent activation of Pyk2 and 
reactive oxygen species have been considered to be essential for EGF-R 
transactivation. 
However, there is evidence that transactivation includes also extracellular 
events. Activated AT1-receptor on vascular smooth muscle cells causes the 
release of intermediatory signaling molecules, such as PKC and reactive 
oxygen species (ROS). These in turn induce a metalloproteinase-dependent 
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cleavage of heparin-binding epidermal growth factor (HB-EGF), which proceeds 
to activate the EGF receptor and its downstream signaling pathways (Prenzel et 
al., 1999; Shah and Catt, 2003; Ushio-Fukai et al., 2001a). This process has 
been termed a triple membrane passing signal event (TMPS) (Harris et al., 
2003). As apparent from its name, HB-EGF possesses not only EGF-like 
properties but also a heparin-binding domain that binds to heparan sulfate side 
chains in heparan sulfate proteoglycanes which serve as co-activators of 
EGF-R. Noteworthy, HB-EGF has been linked to hyperplasia and 
atherosclerosis in VSMCs (Raab and Klagsbrun, 1997). 
8 The scaffolding protein Grb2-associated binder 1 (Gab1) 
A major challenge of research is to determine how the initial activation of growth 
factor receptors leads to multiple downstream signaling cascades. As 
mentioned above, the tyrosine phosphorylation of the receptors generates 
docking sites for several molecules containing Src homology-2 (SH2) or 
phosphotyrosine-binding (PTB) domains. These proteins in turn can be divided 
in two categories, enzymes or transcription factors (e.g. PLCγ, Stats) or 
adaptors (e.g. Grb2). The latter typically lack intrinsic catalytic activity but they 
associate with one ore more enzymes. 
There are various signaling cascades using 'scaffolding adaptors'. These 
scaffolding adaptors contain a membrane-targeting sequence (e.g. pleckstrin 
homology (PH) domain) and multiple tyrosine phosphorylation sites that serve 
as docking sites for additional SH2- or PTB-domain containing proteins (Gu and 
Neel, 2003). Unlike adaptors such as Grb2, scaffolding proteins can be targeted 
to specific membrane lipids. Scaffolding adaptors assemble multimeric signaling 
complexes due to their ability to multiple signal relay proteins. Although only 
little is know about the scaffolding protein so far, they seem to be some kind of 
amplifier for intracellular signaling (Rodrigues et al., 2000; Gu and Neel, 2003). 
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8.1 Gab1 – identification and function 
Gab proteins encompass a family of scaffolding proteins which are conserved 
from worms to mammals. The family of proteins consists of Gab1, Gab2, Gab3, 
Drosophila Dos, and Caenorhabditis elegans Soc1. Concerning this study the 
following paragraphs will focus on Gab1. 
Gab1 was identified in a search for Grb2 SH3-domain binding proteins and it is 
expressed ubiquitously (Holgado-Madruga et al., 1996). It contains an 
N-terminal PH domain, proline-rich motifs and multiple potential tyrosine and 
serine/threonine phosphorylation sites. 
Gab1 is recruited to activated RTKs mostly via Grb2. The role of the PH domain 
in Gab recruitment is best understood for EGF-R signaling. Briefly, Gab1 is 
initially targeted to the EGF-R via Grb2, whereupon it becomes tyrosine 
phosphorylated and interacts with the p85 subunit of PI3K (Rodrigues et al., 
2000). This leads to activation of PI3K and the generation of 3-phosphoinositide 
lipids. The Gab1 PH domain then binds to these lipids, resulting in Gab1 
retention near the receptor and more sustained signaling. In agreement with this 
model, the PH domain is required for maximal EGF-induced Gab1 tyrosine 
phosphorylation and activation of downstream effectors (Rodrigues et al., 
2000). 
9 SH2-containing protein phosphatase 2 (Shp-2) 
Several signaling pathways are regulated via tyrosine phosphorylation. This 
phosphorylation can result in altered enzyme activity, assembly of signaling 
complexes, and protein localization which in turn trigger downstream signaling 
events. The dimension of tyrosine phosphorylation can be regulated by two 
types of enzymes: protein-tyrosine kinases (PTKs), which catalyze 
phosphorylation, and protein-tyrosine phosphatases (PTPs), which direct 
dephosphorylation. Elucidation of these processes are major aims of current 
signal transduction research. 
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Src homology-2 (SH2) domain-containing phosphatases (Shps) are a small, 
highly conserved subfamily of protein-tyrosine phosphatases which are 
expressed in both vertebrates and invertebrates. There are two vertebrate 
Shps – Shp-1 and Shp-2. Drosophila and Caenorhabditis elegans each have 
one Shp ortholog, Corkscrew (Csw) and Ptp-2, respectively. Shp-2 is expressed 
ubiquitously in mammalian cells, whereas Shp-1 expression is more restricted 
with highest levels in hematopoietic cells (Neel et al., 2003). Shp-2 contains two 
N-terminal SH2 domains (N-SH2 and C-SH2), a PTP domain and a C-terminal 
tail. The basal activity of Shp-2 is low owing to allosteric inhibition of its PTP 
domain by the N-terminal SH2 domain. Upon Shp-2 binding to Gab1 protein, 
basal inhibition is relieved, resulting in strong activation. 
9.1 Function of Shp-2 
In most RTK signaling pathways, Shp-2 is required for full activation of the Erk 
MAP kinase pathway. Although Shp-2 clearly regulates Ras/Erk activation, 
genetic and biochemical evidence indicate additional roles (Neel et al., 2003). 
Shp-2 mutant fibroblasts have shown an increased JNK activation in response 
to various stress stimuli (Shi et al., 1998). Moreover, in some RTK (e.g. PDGFR 
and IGFR) pathways, Shp-2 is required for PI3K activation (Wu et al., 2001; 
Zhang et al., 2002). In others (e.g. EGFR signaling), Shp-2 negatively regulates 
PI3K activation by dephosphorylating PI3K-binding sites on Gab1 (Zhang et al., 
2002). 
10 Platelet-derived growth factor (PDGF) 
Platelet-derived growth factors (PDGFs) were identified in 1974 as constituent 
of whole blood serum that was able to stimulate vascular smooth muscle cell 
proliferation (Ross et al., 1974). PDGF was initially purified from human 
platelets and it was one of the first growth factors to be characterized. In 
addition, it has, to some extend, served as a model for growth factor studies in 
general. 
B Introduction 20 
10.1 The isoforms – structure and activation 
The PDGF family consists of four different proteins, PDGF-A, PDGF-B, 
PDGF-C, and PDGF-D, encoded by four different genes. About thirty years ago, 
PDGF-A and PDGF-B, the classical PDGF chains, were discovered. PDGF-A 
consists of 196 or 211 amino acid residues due to alternative splicing and 
PDGF-B is 241 amino acids in length. PDGF-C and PDGF-D were discovered 
more than 20 years later (Li et al., 2000; LaRochelle et al., 2001) and are 
composed of 345 and 370 amino acids, respectively. The PDGF chains form 
homo- and heterodimers, of which five different dimeric isoforms have been 
described so far: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD. A 
highly conserved growth factor domain, referred to as the PDGF/VEGF 
homology domain is present in each of the four PDGF chains. This domain 
consists of approximately 100 amino acids and is characterized by eight highly 
conserved cysteine residues. Two of the cysteines (the second and fourth) are 
involved in disulfide bonds between the two subunits in the PDGF dimer, and 
the other six are engaged in intrachain cysteine bonds (the first pairs with the 
sixth, the third with seventh and the fifth with the eighth). X-ray crystallography 
of the structure of PDGF-BB revealed that the two subunits of the growth factor 
dimers are arranged in an anti-parallel fashion (Oefner et al., 1992). The 
subunits consist of a knot-like structure in which one of the intramolecular 
disulfides reaches through the cavity formed by the two other ones and the 
interjacent sequences (Murray-Rust et al., 1993).  
All four PDGFs are synthesized as precursor molecules and proteolytic 
processing is necessary for their activation and biological function. However, 
there is an important difference in the mechanism. In the classical PDGFs A 
and B the amino-termini are intracellularly processed in the trans-Golgi network 
during protein maturation and secretion. In contrast, PDGF-C and PDGF-D are 
cleaved by extracellular proteases to be activated (Fredriksson et al., 2004). 
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10.2 PDGF receptors 
The α- and β-receptors have molecular sizes of ~170 and 185 kDa, 
respectively. Extracellularly, each receptor contains five immunoglobulin-like 
domains, whereas intracellularly there is a tyrosine kinase domain that contains 
a characteristic inserted sequence without homology to kinases. The five 
dimeric isoforms of PDGF show different capabilities of binding to the two 
existing PDGF receptors (PDGF-Rs). PDGF-A, PDGF-B and PDGF-C bind to 
PDGF-Rα while PDGF-Rβ can be bound and activated by PDGF-B and 
PDGF-D (Fredriksson et al., 2004). Given that the PDGF isoforms are dimeric 
they bind two receptors simultaneously and thus dimerize the receptors upon 
binding. From this results a receptor binding specificity of the five dimeric 
isoforms as shown in figure 2. Dimerization of the PDGF receptors leads to their 
autophosphorylation. This phosphorylation serves two important functions: on 
one hand, phosphorylation of conserved tyrosine residues inside the kinase 
domain (Tyr849 in the α-receptor and Tyr857 in the β-receptor) results in an 
increase in the catalytic activities of the kinases. On the other hand, 
autophosphorylation of tyrosine residues outside the kinase domain generates 
docking sites for SH2 domain containing signal transduction molecules. The 
SH2 domain is a conserved motif of ~100 amino acids that can bind 
phosphorylated tyrosines in a specific environment (Pawson and Scott, 1997). A 
large number of SH2 domain containing proteins have been shown to bind to 
the PDGF receptors. Some of these molecules are themselves enzymes, such 
as PI3-K, PLC-γ, the Src family of tyrosine kinases or the phosphotyrosine 
phosphatases Shp-2. Other molecules such as Grb2, Shc, and Crk lack 
enzymatic activity and serve as adaptor molecules, linking the receptor to 
downstream catalytic molecules. 
It has been shown that PDGF initiates stimulatory and inhibitory signals often in 
parallel (Heldin, 1997). Furthermore, there is evidence that this phenomenon is 
owing to activation of different receptors. While PDGF-Rβ more often mediate 
positive chemotactic and mitogenic signals, PDGF-Rα may mediate either 
positive or negative signals, depending on the cell type (Vassbotn et al., 1992; 
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Yokote et al., 1996; Siegbahn et al., 1990; Koyama et al., 1992; Koyama et al., 
1994). In VSMCs it has been shown that PDGF-BB exerts positive chemotactic 
and proliferative effects (Bornfeldt et al., 1994; Kundra et al., 1994). 
 
α βα α β
PDGF-CC PDGF-AA PDGF-AB PDGF-BB PDGF-DD
Isoform
Receptor
type β  
Figure 2. Receptor binding specificity of the five PDGF isoforms. The ability of the five 
different dimeric isoforms of PDGF to bind and activate homo- and heterodimeric complexes of 
PDGFRα and PDGFRβ are indicated by solid arrows. The dashed arrows indicate that receptor 
heterodimers can be activated. The figure is adopted from Li et al. (Li and Eriksson, 2003) 
10.3 PDGF in physiology and pathophysiology 
PDGF fulfills important functions during embryogenesis, in particular for the 
development of the kidneys, the lungs, the CNS and blood vessels (Leveen et 
al., 1994; Soriano, 1994; Yeh et al., 1991; Sasahara et al., 1991). In these 
organs, connective tissue-like cell types are dependent on PDGF. The 
significant role of PDGF in the formation of connective tissue is also important 
during wound healing in the adult.  
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Moreover, aberrant synthesis of PDGF and concomitant autocrine growth 
stimulation are an important step in the development of diseases such as 
atherosclerosis or cancer. Animal models established a role for PDGF signaling 
in cardiovascular disease. For example, balloon injury of a normal vessel is a 
well accepted model to examine the role of different cell types and growth 
factors. mRNA levels of PDGF and its receptors are increased in the rat carotid 
artery after percutaneous transluminal coronary angioplasty (PTCA) and most 
luminal VSMCs are strongly positive for PDGF and its receptors (Majesky et al., 
1990). Further experiments investigated the actions of PDGF in vivo by infusing 
PDGF-BB into the rat carotid artery after a gentle, filament-mediated endothelial 
denudation without injuring the underlying medial VSMCs. The resulting data 
support a role for stimulation of migration, proliferation and altered gene 
expression of VSMCs by PDGF-BB (Jawien et al., 1992; Bendeck et al., 1996). 
11 Phosphatidylinositol 3-kinases 
11.1 Phosphatidylinositols (PtdIns) 
PtdIns are composed of glycerol, two fatty acids and inositol 1-phosphate. 
Glycerol builds the backbone. In physiologic conditions, stearic acid is attached 
at position 1 while at position 2 arachidonic acid is attached. Inositol 
1-phosphate is bound to position 3 (Payrastre et al., 2001). The inositol residue 
can be phosphorylated additionally at positions 3, 4 and 5. These 
phosphorylated derivates are referred to as phosphoinositides (PtdInsPs) 
(Payrastre et al., 2001; Vanhaesebroeck and Alessi, 2000). By further 
processing, these phospholipids can take on different functions. 
Phospholipases can cleave the inositol thus generating inositol tri-phosphate 
(IP3) which serves as second messenger. Interaction with intracellular proteins 
or changes in the topology of membranes are two other possibilities (Payrastre 
et al., 2001). 
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11.2 Phosphatidylinositol 3-kinases – classification, activation and 
inhibition 
There are three different kinds of kinases capable of phosphorylating 
phosphatidylinositol or phosphoinositides: phosphoinositide 3-kinases (PI3Ks), 
phosphoinositide 5-kinases and phosphoinositidephosphate 4-kinases. PI3Ks 
are responsible for the production of PtdIns(3)P, PtdIns(3,5)P2, PtdIns(3,4)P2 
and phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3). They are not 
substrate of any known PLC and function as second messengers by interacting 
directly with functional protein domains, such as pleckstrin homology domains 
(PH). Class I PI3Ks are the only enzymes that use PtdIns(4,5)P2 as a substrate 
to synthesize PtdIns(3,4,5)P3 (Rameh and Cantley, 1999). The latter is of 
special interest as it is a prerequisite to activate the serine/threonine kinase Akt, 
the primary mediator of PI3K-initiated signaling (see also chapter 12) (Payrastre 
et al., 2001; Cantley, 2002). 
Quiescent cells only contain significant levels of PtdIns(3)P, whereas other 
3-phosphorylated phosphoinositides can hardly be found. After cellular 
stimulation, however, there is a drastic increase in 3-phosphorylated 
phosphoinositides (Vanhaesebroeck et al., 2001). Class I PI3Ks seem to 
phosphorylate primarily PtdIns(4,5)P2, in vivo, thereby generating 
PtdIns(3,4,5)P3. The termination of PI3K signaling by degradation of 
PtdIns(3,4,5)P3 can by mediated by phosphatases such as the PTEN tumor 
suppressor protein which can dephosphorylate PtdIns(3,4,5)P3 at the 3-position 
and the Src homology-2 (SH2)-containing phosphatases, which 
dephosphorylate at the 5-position (Cantley, 2002). 
Class I PI3Ks can be divided into two subclasses, class IA and class IB. Class 
IA PI3Ks are composed as heterodimers of the following: an inhibitory 
adaptor/regulatory (p55 / p85) subunit which p85 as prototype and a catalytic 
(p110) subunit. p85 exists in two subclasses (p85α/p85β) and contains a Src 
homology-3 (SH3) domain, a breakpoint cluster-region, two proline rich regions 
as well as two carboxy-terminal SH2 domains separated by an inter-SH2 
region. This region mediates the binding of p85 to the catalytic subunit p110 
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(Wymann and Pirola, 1998). The SH2 domain of p85 exerts two functional 
activities. First, it binds to phospho-tyrosines being displayed on receptor 
tyrosine kinases after growth factor stimulation. Thereby, PI3K is targeted to the 
membrane leading to an increased activity of PI3K. The second function 
consists in p85 binding and integrating signals from various cellular proteins, 
including intracellular proteins such as PKC, Shp-2, Rac, Rho, Ras and Src, 
providing an integration point for activation of p110 and downstream molecules 
(Hennessy et al., 2005). 
There are three known isoforms of class IA p110 (p110α, p110β, p110δ), which 
contain an amino-terminal p85/p55-interacting region, a domain that binds to 
Ras, a phosphoinositide 3-kinase family accessory domain (PIK domain), which 
function is not fully clear yet but it is believed to be involved in substrate 
presentation (Flanagan et al., 1993), and a carboxy-terminal catalytic domain.  
Class IB PI3Ks consist of p110γ and a regulatory subunit p101. They are 
activated directly by G-protein coupled receptors and indirectly by other 
receptors. Of note, all class I PI3Ks also possess intrinsic serine/threonine 
protein kinase activity (Hennessy et al., 2005). 
Two chemical, cell permeable inhibitors have been used to inhibit the function of 
PI3K: wortmannin, a fungal metabolite that irreversibly inhibits p110 by covalent 
modification of the catalytic subunit (Wymann et al., 1996), and the flavonoid 
derivative LY294002 a reversible, competitive inhibitor of the ATP binding site. 
However both inhibitors exhibit off-target activity, when used in higher doses 
than required for PI3K inhibition (Fruman et al., 1998).  
12 Akt and mitogen-activated protein kinases (MAPKs) 
12.1 Protein kinase B (PKB) / Akt 
Akt was initially identified as a homologue of the oncogene v-Akt, encoded by 
the genome of the murine lymphoma virus AKT8. Due to sequence homologies 
with protein kinase A (PKA) and protein kinase C (PKC), Akt is also referred to 
as protein kinase B (PKB) (Vogt et al., 2006). It is a member of the AGC 
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(protein kinase A / protein kinase G / protein kinase C-like) class of 
serine/threonine kinases. Like the other members of the AGC-family, Akt 
requires phosphorylation to be activated. Except a spliced isoform of PKBγ/Akt3 
all members need to be phosphorylated at two residues: a threonine (residue 
308 in PKBα/Akt1) within the kinase t-loop and a serine in the hydrophobic motif 
(serine 473 in PKBα/Akt1). The activation of Akt depends on the generation of 
3-phosphorylated phosphoinositides generated by class I PI3-kinases. These 
lipids interact with the PH domain present in proteins including Akt and 
phosphoinositide-dependend kinase 1 (PDK1), thereby recruiting these proteins 
to the membrane (Scheid and Woodgett, 2001). 
This relocation from the cytoplasm to the inner surface of the plasma membrane 
places Akt, the primary mediator of PI3K-initiated signaling, in close proximity to 
the regulatory kinases responsible for its phosphorylation and activation. Upon 
binding to PIP3, Akt undergoes conformation changes that allow the 
phosphorylation by PDK1 at Thr308 in the activation loop. Subsequent 
phosphorylation at Ser473 by a still unidentified kinase, referred to as PDK2, 
results in full Akt activation (figure 3). Possible PDK2 candidates are integrin-
linked kinase, Akt itself, PDK1, DNA-dependent protein kinase, mitogen-
activated protein kinase-activated protein kinase 2 (MAPKAPK-2) or the 
TOR/Rictor complex (Nicholson and Anderson, 2002; Vogt et al., 2006; 
Taniyama et al., 2004).  
The serine/threonine phosphatases PP2A is responsible for the inactivation of 
Akt (Millward et al., 1999). 
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Figure 3. Activation of PKB/Akt downstream of EGF receptor. Recruitment of PI3K to the 
activated EGF-R via the adaptor molecule Gab1 generates 3-phosporylated phosphoinositides 
at the membrane which serve as an anchor for PH domain containing proteins. At the 
membrane Akt is phosphorylated by PDK1 and a yet unidentified kinase (termed PDK2). Active 
Akt translocates to the cytosol and the nucleus. Inactivation occurs via protein phosphatase 2A. 
The figure is adopted from Vanhaesebroeck and Alessi, 2000 (Vanhaesebroeck and Alessi, 
2000). 
Among the first identified Akt substrates was glycogen synthase kinase 3 
(GSK3). This protein is inactivated upon phosphorylation. Akt triggers a 
signaling network that positively regulates G1/S cell cycle progression through 
inactivation of GSK3 (Liang and Slingerland, 2003). By phosphorylating GSK3, 
Akt stabilizes or even activates GSK3 targets such as cyclin D, c-Myc and 
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glycogen synthase, enzymes involved in the progression of the cell cycle 
(Cohen and Frame, 2001).  
Further Akt targets belong to the FOXO family of transcription factors. These 
factors enhance e.g. transcription of the cell cycle inhibitor p27Kip1. 
Phosphorylation of FOXO transcription factor results in inactivation via 
cytoplasmic retention or inhibition of DNA binding (Burgering and Kops, 2002; 
Scheid and Woodgett, 2003; Liang and Slingerland, 2003). 
Akt is also referred to as survival kinase in that it is able to inactivate the pro-
apoptotic proteins BAD and caspase 9 by phosphorylation, which leads to 
cellular survival. 
Akt supports protein synthesis, as it occurs in hypertrophy. It does so via 
phosphorylation and activation of mammalian target of rapamycin (mTOR). This 
effect is promoted by the GSK3-dependent activation of eukaryotic initiation 
factor 2B (eIF2B) (Cohen and Frame, 2001; Scott et al., 1998).  
The Akt pathway includes a cross-talk between Akt and Erk1/2. This cross-talk 
eventually leads to inactivation of the Erk1/2 pathway (Galetic et al., 2003; 
Reusch et al., 2001). 
12.2 MAPKs 
Mitogen-activated protein kinases (MAPKs) are a highly conserved, ubiquitously 
expressed family of serine/threonine kinases which control a great variety of 
cellular processes, such as transformation, differentiation, apoptosis and cell 
growth. These kinases require a dual phosphorylation to be activated. Specific 
phosphatases are responsible for the inactivation of MAPKs. This interplay of 
phosphorylation and dephosphorylation enables the cell to rapidly adjust its 
requirement of active or inactive MAPKs (Johnson and Lapadat, 2002). 
MAPKs are activated and regulated by a signaling cascade comprised of three 
successively activated kinases. MAPKs are activated by highly selective MAPK 
kinases (MKK or MEK), which are in turn activated by MAPK kinase kinases 
(MKKK or MEKK) (figure 4). Major targets of the MAPKs are other protein 
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kinases, phospholipases and last but not least transcription factors (Johnson 
and Lapadat, 2002). 
MKKK
MKK
MAPK
A-Raf, B-Raf,
Raf1
MEK1/2
Erk1/2
MEKK1-4,
ASK1, …
MEK4/7
JNK1/2/3
TAK, ASK1,
MLK2, …
MEK3/6
p38
Target proteins  
Figure 4. The MAPK cascade. The modules shown are representative of pathway connections 
for the respective MAPK. The left column represents the general cascade, whereas the second 
to fourth column show the three subfamilies of Erk, Jnk and p38. There are multiple component 
MKKKs, MKKs, and MAPKs for each system. Mitogens and cellular stresses lead to activation 
of these cascades. 
To date, several distinct groups of MAPKs have been characterized in 
mammals: extracellular signal-regulated kinases (Erks) 1 and 2 (Erk1/2), c-Jun 
amino-terminal kinases (JNKs) 1, 2, and 3, p38 isoforms α, β, γ, and δ, 
Erk5/BMK1 and the orphan MAPKs Erks 3, 7, nemo-like kinase (NLK) and MOK 
(Chen et al., 2001; Kondoh et al., 2005; Kyriakis and Avruch, 2001). 
Three of these subfamilies of the MAPKs are of interest for this study. The 
extracellular-signal regulated kinases (Erk1/2) are critically involved in 
proliferation upon mitogenic stimulation. Targets are cytoplasmic proteins, 
membrane proteins, cytoskeletal proteins, and nuclear proteins including 
transcription factors (Chen et al., 2001). The c-Jun N-terminal kinases (JNKs), 
also referred to as stress activated protein kinases (SAPK), activate the 
transcription factor c-Jun, a constituent of the transcription factor AP-1 
(Takahashi and Berk, 1998). The p38 MAPK isoforms regulate the production of 
key inflammatory mediators, including TNF-α, IL-1β , and COX-2. Further it has 
been shown to be crucially involved in the regulation of the cell cycle 
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(Ambrosino and Nebreda, 2001; Bulavin and Fornace, Jr., 2004; Schieven, 
2005). 
13 Caveolins 
The discovery of caveolae is accredited to the Nobel laureate George Emil 
Palade (Palade, 1953), who called them plasmalemmal vesicles. Two years 
later, E. Yamada described similar structures in the gall bladder epithelium, 
naming them caveolae intracellulares due to their appearance (YAMADA, 
1955). Caveolae are flask-shaped vesicular invaginations of the plasma 
membrane 50–100 nm in diameter. The main structural proteins of caveolae are 
the caveolins. The latter form a scaffold onto which many classes of signaling 
molecules can assemble to generate preassembled signaling complexes. In 
addition to concentrating these signal transducers within a distinct region of the 
plasma membrane, caveolin binding may functionally regulate the activation 
state of caveolae-associated signaling molecules. In recent years interest in 
caveolae increased more and more due to improved insight in caveolin function 
and caveolae-associated signal transduction (Williams and Lisanti, 2004b). 
Caveolin proteins are expressed in most of the cell types that play a role in the 
development of atherosclerosis. These cells include endothelial cells, 
macrophages and smooth muscle cells (Frank and Lisanti, 2004). The next 
paragraphs will show recent findings essential for this study. 
13.1 Discovery and structure 
The caveolin gene family has three members in vertebrates: caveolin-1, 
caveolin-2, and caveolin-3. The caveolins are integral membrane proteins of 
18-24 kDa. Structurally, caveolin can be roughly divided into three distinct 
domains: the hydrophilic amino-terminal, the hydrophobic central stretch and 
the hydrophilic carboxy-terminal. They assume an unusual hairpin-like structure 
within the membrane, with both amino and carboxy terminus facing the 
cytoplasm (Schlegel et al., 1998) (figure 5 A+B). This atypical membrane-
spanning model is supported by findings that antibodies against the amino or 
31 Caveolins  
carboxy terminus of caveolin-1 need permeabilized cells in order to bind 
caveolin-1. Moreover cell-surface biotinylation is not capable of labeling 
caveolin-1. Finally, palmitoylation and tyrosine phosphorylation of both the 
amino and carboxy-terminal domains provide further evidence of this 
assumption since both reactions are post-translational modifications exclusively 
located in the cytoplasm (Williams and Lisanti, 2004a). Caveolin-1 (also known 
as caveolin, Cav-1, or VIP21) is ubiquitously expressed with highest levels in 
adipocytes, endothelial and smooth muscle cells. It was the first member of the 
caveolin family to be described. It was shown to be a structural constituent of 
caveolae (Rothberg et al., 1992) and was isolated as one of several proteins 
that became phosphorylated on tyrosine residues in chicken embryo fibroblasts 
transformed with the v-Src oncogene (Glenney, Jr. and Zokas, 1989). Cloning 
of the Cav-1 cDNA revealed that it was identical to another protein, VIP21, 
which had been cloned almost simultaneously (Glenney, Jr. and Soppet, 1992; 
Kurzchalia et al., 1992). Interestingly, VIP21 was isolated as an integral 
membrane protein component of transport vesicles derived from the trans-Golgi 
network in Madin-Darby canine kidney (MDCK) cells, suggesting that 
Cav-1/VIP21 may have a role in molecular trafficking as well as oncogenesis. 
Further studies revealed that caveolin-1 can be subdivided in two isoforms (α 
and β) from which the β-isoform was originally thought to arise from an internal 
translational start site but it has recently been shown to be translated from 
different mRNA than caveolin-1α (Krajewska and Maslowska, 2004). 
Caveolin-1β is 31 amino acids shorter compared to the α-isoform. 
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Figure 5 Primary structure and topology of caveolin-1. A, the current view of caveolin-1 
localization in the plasma membrane. Two caveolin-1 monomers forming a dimmer are shown 
for simplicity. Usually 14-16 monomers self-associate to form a single caveolin homo-oligomer 
or hetero-oligomer with caveolin-2 (not shown). Modified from Razani et al. (Razani et al., 
2002b). B, caveolin-1 domains. Note that the amino-terminal membrane-attachment domain is 
also referred to as the caveolin scaffolding domain (CSD). 
Caveolin-2 and caveolin-3 were both identified in 1996. Caveolin-2 was 
discovered by microsequencing of a 20kDa protein that co-purified with 
adipocyte-derived caveolar membranes (Scherer et al., 1996). Caveolin-2, 
similarly to caveolin-1, has been found to exist in multiple isoforms that differ in 
the length of their amino-terminal part. Without caveolin-1, caveolin-2 exists 
mainly as monomer or homodimer that is retained at the level of the Golgi 
complex (Krajewska and Maslowska, 2004; Manninen et al., 2005). 
Caveolin-3 (also known as M-caveolin; a muscle specific member of the 
caveolin family) was identified through database search and traditional cDNA 
library screening in attempt to find caveolin-1 homologues (Way and Parton, 
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1995; Tang et al., 1996). It is closely related to caveolin-1 as shown by protein 
sequence homology. It is able to form stable homooligomers and its expression 
is sufficient to generate caveolae (Krajewska and Maslowska, 2004). 
13.2 Localization and functions in pathology 
Some groups consider caveolae to be a subset of lipid rafts, highly ordered 
microdomains within the plasma membrane. However, since some proteins are 
known to localize selectively to either lipid rafts or caveolae but not both this 
assumption may not be completely accurate (Williams and Lisanti, 2004a). One 
evidence for the thesis that lipid rafts and caveolae are separate entities is that 
lipid rafts do not contain caveolins and caveolae lack glycosyl-
phosphatidylinositol-anchored proteins (Li et al., 2005). Current research is 
establishing the importance of caveolins in modulating the development and 
progression of a variety of diseases. The following paragraphs will show where 
the caveolins are expressed and will give a brief synopsis of the involvement of 
caveolins in various pathological disorders, especially related to the 
cardiovascular system. 
Since caveolin-3 has been identified as the main caveolar protein expressed in 
skeletal and cardiac myocytes, extensive research has elucidated its imolication 
in skeletal myopathies such as rippling muscle disease (RMD), distal myopathy 
(DM), and idiopathic hyperCKemia (Betz et al., 2001; Kubisch et al., 2003; 
Carbone et al., 2000; Woodman et al., 2004). 
Previous studies showed that caveolin-2 is coexpressed with caveolin-1 in most 
cell types and colocalizes with caveolin-1 in caveolae, forms hetero-oligomers 
with caveolin-1, and requires caveolin-1 for proper membrane localization. It 
has been proposed that caveolin-2 may function as an accessory protein of 
caveolin-1 (Krajewska and Maslowska, 2004). However, caveolin-2 deficient 
mice show evidence of severe pulmonary dysfunction without disruption of 
caveolae indicating a selective role of caveolin-2 in mammalian physiology 
independent of caveolin-1 (Razani et al., 2002a). 
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Caveolin-1 is most abundantly expressed in terminally differentiated cells such 
as epithelial and endothelial cells, adipocytes, fibroblasts, and smooth muscle 
cells (Glenney, Jr., 1992; Kurzchalia et al., 1992; Kurzchalia et al., 1994; 
Rothberg et al., 1992). Depending on cell type caveolin-1 seems to exist either 
as soluble cytoplasmic form or as secreted form (Liu et al., 2002; Krajewska 
and Maslowska, 2004) and the 31 amino acids lacking in the β-isoform seem to 
play a role in selectively targeting the isoforms to different cellular 
compartments (Williams and Lisanti, 2004a). 
As mentioned above, post-translational modifications take place in both the 
amino-terminal and the carboxy-terminal domains. The C-terminus is 
palmitoylated on three cysteine residues at positions 133, 143, 156, while the 
N-terminus is phosphorylated at tyrosine 14 (Stan, 2005). The function of the 
palmitate chains seems to be complex. They possibly anchor the carboxy-
terminal region to the membrane and they may increase the stability of the 
oligomers and therefore the scaffold structure of caveolae as well (Krajewska 
and Maslowska, 2004). Caveolin-1 selectively binds cholesterol and affects 
cholesterol homeostasis and it has been suggested that at least two palmitate 
chains are required for the binding and transport of cholesterol (Uittenbogaard 
and Smart, 2000; Fielding and Fielding, 2001). 
The tyrosine phosphorylation is essential for protein-protein interaction. 
Mutation of the tyrosine 14 residue that prevents phosphorylation was shown to 
impair association with the Grb7 protein involved in signal transduction (Lee et 
al., 2000). 
Involvement in cellular transformation was the first feature of caveolin-1 to be 
suggested as it was identified as a substrate for v-Src in transformed chicken 
embryo fibroblasts (Glenney, Jr., 1989). Further studies revealed that caveolin-1 
levels in oncogenically transformed cells are often down regulated and 
increased growth correlates with a loss of caveolin-1 expression (Koleske et al., 
1995). Cardiovascular disorders such as vascular dysfunction, atherosclerosis 
and neointimal hyperplasia strongly correlate with caveolin-1 deficiency. 
Caveolin-1 null mice display vascular dysfunction, with defects in endothelium-
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dependent contraction, mediated mainly through the loss of inhibition of eNOS 
activity (Razani et al., 2001; Drab et al., 2001). The potent eNOS inhibiting 
activity of caveolin-1 was demonstrated using cell permeable proteins linked to 
the CSD (Bucci et al., 2000). Vascular permeability is another feature to be 
linked to caveolin-1 function. Endothelial cells highly express caveolin-1 and the 
latter is clearly linked to transcytotic processes, as aortic ring segments from 
caveolin-1 null mice do not efficiently take up macromolecules, such as albumin 
(Schubert et al., 2001). The importance of caveolin-1 in maintaining vascular 
tone, permeability, and normal physiology suggests that caveolin-1 may have a 
role in pathogenic vascular conditions such as atherosclerosis. Further 
evidence for this assumption was provided by a recent study where neointimal 
hyperplasia was significantly enhanced in the carotid arteries of caveolin-1 null 
mice (Hassan et al., 2004). 
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C MATERIALS AND METHODS 
1 Stock solutions  
1.1 Preparation of Angiotensin II (Ang II) solution 
Ang II (Sigma) was dissolved in 0.25 % sterile BSA solution (Roche) and stored 
at -80°C as a 2 mM stock solution. For working aliquots the stock solution was 
diluted to 20 µM with 0.25 % BSA and stored at -20°C. 100 nM Ang II were 
used for experiments. 
1.2 Preparation of EGF solution 
Following a quick centrifugation of the vial containing the EGF lyophilisate 
(Upstate), a 100 µg/ml stock solution (EGF) was prepared in sterile phosphate 
buffered saline (PBS; see also paragrapgh 2.2) and stored at -20°C. 100 ng/ml 
EGF was used for experiments. 
1.3 Preparation of PDGF-BB solution 
After a quick centrifugation, lyophilized, rec. PDGF-BB (Bachem) was 
reconstituted in 10 mM acetic acid to a concentration of 100 µg/ml. This solution 
was then diluted with sterile PBS + 0.1 % BSA to a concentration of 10 µg/ml 
and stored at -20°C. 20 ng/ml PDGF was used for experiments. 
1.4 Preparation of Resveratrol (RV) 
trans-resveratrol (Sigma) was dissolved in DMSO to concentrations of 50 or 
100 mM respectively and stored at -20°C. 
1.5 Preparation of caffeic acid phenethyl ester (CAPE) solution 
5 mM stock solutions of CAPE (Calbiochem) were prepared in DMSO and 
stored in 15µl aliquots at -20°C. 
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2 Cell Culture 
2.1 Bovine serum  
Bovine serum (Invitrogen) was heat inactivated for 30 minutes at 56°C and 
stored at -20°C. 
2.2 Solutions 
PBS 
NaCl  7.20 g 
Na2HPO4  1.48 g 
KH2PO4  0.43 g 
H2O ad 1000.0 ml 
 
PBS⊕ 
NaCl  8.00 g 
KCl  0.20 g 
Na2HPO4  1.15 g 
KH2PO4    0.20 g 
MgCl2 x 6 H2O 0.10 g 
CaCl2 x 2 H2O  0.10 g 
H2O ad 1000.00 ml 
 
TBS-T 
Tris-base  3.0 g 
NaCl  11.1 g 
Tween-20 2.0 ml 
H2O ad 1000.0 ml 
 
Trypsin/EDTA (T/E) 
Trypsin  0.05 g 
(diluted 1+249 in PBS) 
EDTA  0.20 g 
PBS ad 100.0 ml 
 
Digestion buffer 
Collagenase  0.100 g 
(272 U/mg) (Biochrom) 
HEPES  0.240 g 
Ascorbic acid  0.005 g 
BSA  0.100 g 
HAM’s F12 ad 100.000 ml 
medium  
(Pan Biotech) 
 
Freezing medium 
DMEM   8.0 ml 
DMSO  1.1 ml 
Bovine serum  2.0 ml 
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2.3 Cells 
For all experiments with CAPE VSMCs from male Sprague-Dawley rat (Charles 
River Wiga) thoracic aortas were used unless stated otherwise. 
3T3 immortalized fibroblasts from Shp-2 exon 3-/- (Shp-2∆46-110) mice were 
described previously ( (Saxton et al., 1997); named Shp-2-/-). Shp-2-/- cells 
which contain a stably reconstituted Shp-2 protein via retroviral transfection 
(Zhang et al., 2002) were used as control (Shp-2 rescue 3T3 fibroblasts). All 
Shp-2 mutants were a kind gift of Prof. Benjamin G. Neel, Cancer Biology 
Program, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. The 
fibroblasts were cultured as described for VSMCs. 
2.4 Isolation of VSMCs 
VSMCs were isolated by enzymatic digestion. Aortas were removed and placed 
in PBS⊕ for further preparation. Afterwards, the aortas were opened up and 
placed in digestion buffer (on the basis of (Palmberg et al., 1985)) for 15 
minutes at 37°C. Then the endothelium and adventitia were removed with 
tweezers before mincing the aortas with two scalpells. Subsequently the 
vessels were incubated in digestion buffer for another 4 hours at 37°C. After 
centrifugation at 220g for 10 minutes, cells were placed in a 25 cm² flask and 
grown in DMEM w/o phenol red (BioWhittaker) supplemented with 10 % bovine 
serum (Invitrogen), 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin (growth medium). At least four aortas are needed for one 25 cm² 
flask. VSMCs were identified by fluorescence microscopy using a monoclonal 
anti-α-smooth muscle actin FITC-conjugated antibody (1:250 dilution Sigma) 
(Chamley-Campbell et al., 1979). Human umbilical vein endothelial cells 
(HUVECs), Raw 264.7 and L929 murine fibroblasts were used as negative 
controls to test the specificity of the antibody. However, for most experiments, 
VSMCs kindly provided by Prof. Kathy K. Griendling, Emory University, Atlanta, 
isolated by the same method, were used. 
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2.5 Freezing, storage and thawing of VSMCs 
For freezing, VSMCs from one 75 cm² flask were trypsinized, counted, spun 
down and resuspended in ice-cold freezing medium to a concentration of 
1⋅106 cells/ml. 1 ml aliquots were frozen in cryovials at -20°C for 24 hours, then 
at -80°C for another 24 hours before long time storage at -196°C in liquid 
nitrogen. For thawing, cells were warmed to 37°C and immediately dissolved in 
pre-warmed culture medium. After centrifugation, cells were resuspended in 
culture medium and placed in a 75 cm² flask. 
2.6 Passaging of cells 
Cells were passaged twice a week. Growth medium was removed and cells 
were washed once with 10 ml PBS before incubation with trypsin/EDTA solution 
for approximately 2 minutes to allow detachment of the cells. Cells were 
disseminated with 1⋅106 or 1.9⋅106 cells respectively in 75 cm² culture flasks. 
For experiments VSMCs were disseminated in appropriate plates. Cells were 
cultured between passage 7 and 15 in 6- or 24-well plates or 60 mm dishes and 
used at 80-90 % confluence. 
When Ang II or EGF was used for stimulation, cells were serum-starved in 
DMEM containing 0.1 % bovine serum overnight prior to experiments. For 
serum-stimulation or stimulation with PDGF cells were rendered quiescent by 
cultivation in DMEM without serum for at least 24 hours. 
3 Cell counting 
3.1 Experimental procedure 
Cells were seeded at a density of 100,000 cells/well in six-well plates and kept 
in growth medium for 24 h. After serum starvation for 4 days, cells were pre-
treated with or without 5 µM CAPE for 30 min and subsequently stimulated with 
20 ng/ml PDGF. After serum starvation for 24 hours, cells were pre-incubated 
with vehicle, 5 µM SB203580 or CAPE at the indicated concentrations for 
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30 min and subsequently stimulated with 20 ng/ml PDGF for 48 hours. Cells 
were then trypsinized and the cell number was determined in a trypan blue 
exclusion assay using a Vi-Cell cell counter (Beckman, Krefeld, Germany). 
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4 Western blot analysis 
4.1 Solutions 
Lysis buffer “stock concentrate” 
HEPES 50 mM 
NaCl 50 mM 
EDTA 5 mM 
Na4P2O7 x 10 H2O 10 mM 
NaF 50 mM 
Na2VO4 1 mM 
Bring volume up to 325 ml with H2O. Adjust pH with NaOH at 4°C to pH 7.5. 
Replenish with H2O to a final volume of 430 ml. Store at 4°C. 
Prepare 1x lysis buffer just before use as follows. 
Stock concentrate 8.6 ml 
PMSF 1.0 mM 
Complete® 25x 0.4 ml 
(Roche) 
Triton X-100 1.0 ml 
(10 % in H2O) 
 
SDS sample buffer (stock 
solution w/o β-mercaptoethanol) 
0.5 M TRIS-HCl 37.5 ml 
(pH 6.8) 
SDS 6.0 g 
Glycerol 30.0 ml 
Bromophenol blue 15.0 mg 
H2O ad 100.0 ml 
SDS sample buffer (3x) 
Stock solution 850 µl 
β-mercaptoethanol 150 µl 
 
To prepare 1x solution, add the appropriate amount of water to the 3x solution. 
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Resolving gel 10 % 
Rotiphorese® Gel 30 5.00 ml 
(Roth) 
TRIS-base 3.75 ml 
1.5 M, pH 8.8 
SDS 10 % 0.15 ml 
H2O 6.10 ml 
TEMED 15.00 µl 
APS 75.00 µl 
Stacking gel 
Rotiphorese® Gel 30 1.7 ml 
(Roth) 
TRIS-HCl 1.0 ml 
1.25 M, pH 6.8 
SDS 10 % 0.1 ml 
H2O 7.0 ml 
TEMED 20.0 µl 
APS 100.0 µl 
 
Gels were prepared using Rotiphorese® Gel 30 containing 30 % 
polyacrylamide (PAA)/0.8 % bisacrylamide. Depending on the molecular weight 
of the protein of interest, different concentrations of PAA were used. Before 
addition of TEMED and APS, the solutions were degassed using ultrasound for 
10 minutes. 
Electrophoresis buffer (5x) 
TRIS-base 15.0 g 
Glycine 72.0 g 
SDS 5.0 g 
H2O ad 1000.0 ml 
To prepare 1x solution, add the appropriate amount of H2O to the 5x solution 
Blotting buffer (5x) 
TRIS-base 15.2 g 
Glycine 72.9 g 
H2O ad 1000.0 ml 
 
Blotting buffer (1x) 
Blotting buffer (5x) 200 ml 
Methanol 200 ml 
H2O 600 ml 
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Tris-buffered saline pH 8.0 containing 1 % Tween (TBS-T) 
Tris-base 3.0 g 
NaCl 11.1 g 
Tween-20 1.0 ml 
H2O ad 1000.0 ml 
 
Coomassie staining solution 
Coomassie brilliant 1.5 g 
blue G 
Acetic acid (100 %)50.0 ml 
Ethanol (96 %) 225.0 ml 
H2O ad 500.0 ml 
Coomassie destaining solution 
Acetic acid (100 %) 100 ml 
Ethanol (96 %) 335 ml 
H2O ad 1000 ml 
 
Ponceau stock solution 
Ponceau S  2.0 g 
Acetic acid (100%) 50.0 ml 
H2O ad 100.0 ml 
Dilute the stock solution 1+9 with H2O before usage  
4.2 Principle 
Separation of proteins was performed by denaturing discontinuous SDS-
polyacrylamide gel electrophoresis (SDS-Disc-PAGE) (Laemmli, 1970). Using 
discontinuous electrophoresis, aggregation of proteins entering the gel is 
prevented and sharper bands are obtained. The gel matrix is divided in two 
areas, the narrow porous resolving gel and the wide porous stacking gel. 
Furthermore two different buffers are used. The buffer for the resolving gel 
contains 0.375 mol/l Tris-HCl at pH 8.8, the buffer for the stacking gel contains 
0.125 mol/l Tris-HCl at pH 6.8. The latter pH is near the isoelectric point of 
glycine in the electrophoresis buffer. Thus at the beginning of the 
electrophoresis glycine possesses a low electrophoretic mobility whereas 
chloride anions possess a very high mobility. The proteins to be separated 
exhibit mobilities between those of glycine and chloride. When applying an 
electric field, in this discontinuous system all ions are moving with the same 
speed, building a stack in order of their mobilities. This phenomenon is called 
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isotachophoresis. As soon as the stack reaches the narrow porous resolving 
gel, the proteins receive a frictional resistance and the zone gets sharpened. 
Glycine is not affected and overtakes the proteins thus the system gets 
homogenous and the proteins will now be separated by their size. 
4.3 Experimental procedure 
4.3.1 Sample preparation 
Cells grown in 60 mm dishes were stimulated with the indicated substances for 
the denounced times. RV, CAPE and inhibitors (table 1) were preincubated for 
30 minutes respectively. 
Cells were harvested on ice by washing twice with ice-cold PBS and addition of 
200 µl lysis buffer. After 30 minutes incubating on ice, cells were scraped off 
and lysates were transferred to pre-cooled Eppendorf Tubes®. The 
homogenates were cleared by centrifugation at 14,000 g for 10 minutes at 4°C. 
Protein concentration in the supernatants was determined by the BCA assay 
(figure 6) using a Tecan SunriseTM absorbance reader. The remaining 
supernatants were aliquoted and mixed with 3x lysis buffer. Samples were 
boiled at 95°C for five minutes and stored at -20°C.  
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Figure 6: BCA assay 
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Table 1: inhibitors and stimulants 
Name Concentration Provider 
AG 1478 250 nM Qbiogene-Alexis 
Anisomycin 10µM Sigma 
Aphidicolin 1 µM Calbiochem 
CoPP 10 µM Alexis 
NAC 10 mM Sigma 
PD90580 20 µM Qbiogene-Alexis 
PP1 20 µM Qbiogene-Alexis 
SB203580 5-10 µM Calbiochem 
SnPP 10 µM Alexis 
Wortmannin 50 nM Qbiogene-Alexis 
 
4.3.2 Electrophoresis, tank blotting and protein detection 
Equal amounts of protein were loaded and separated by SDS-Disc-PAGE (Mini 
Protean 3, Bio-Rad, Munich, Germany). Proteins were then transferred either 
for 60 min at 100 V or overnight at 25 V to a nitrocellulose membrane 
(HybondTM ECLTM, Amersham Biosciences) with a Mini Trans-Blot® Cell (Bio-
Rad, Munich, Germany). After blocking with non-fat dry milk (Bio-Rad, Munich, 
Germany) in TBS-T for one hour, primary antibodies (table 2) dissolved in TBS-
T containing 5 % BSA were added and rocked gently overnight at 4°C. 
Subsequently the membranes were washed three times with TBS-T and then 
incubated with appropriate horseradish-peroxidase conjugated secondary 
antibodies (table 3) for one hour at room temperature. Immunoreactive bands 
C Materials and Methods 46 
were detected with an enhanced chemo luminescent detection kit (ECL PlusTM, 
Amersham, Freiburg, Germany) and x-ray films (Fuji) The films were developed 
with an AGFA Crurix 60 (AGFA, Cologne, Germany) and scanned for digital 
analysis. 
Table 2: primary antibodies 
Target  Source Dilution Provider 
Akt rabbit 1:2000 Cell Signaling 
Caveolin 1 mouse 1:1000 BD Biosciences 
EGF-R rabbit 1:1000 Cell Signaling 
Erk 1/2 (p42/44) rabbit 1:5000 Cell Signaling 
HO-1 (HSP32) rabbit 1:1000 Calbiochem 
p70 rabbit 1:2000 Cell Signaling 
phospho-Akt (ser473) rabbit 1:2000 Cell Signaling 
phospho-EGF-R (typ845) rabbit 1:1000 Cell Signaling 
phospho-Erk 1/2 rabbit 1:5000 Cell Signaling 
phospho-p38 rabbit 1:1000 Cell Signaling 
phospho-p70 (thr421/ser424) rabbit 1:2000 Cell Signaling 
phospho-Tyr-100 mouse 1:2000 Cell Signaling 
PI3-kinase p85 rabbit 1:4000 Upstate 
retinoblastoma protein mouse 1:1000 BD Biosciences 
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Table 3: secondary antibodies 
Target Source Dilution Provider 
rabbit IgG HRP-conjugated goat 1:10000 Jackson 
mouse IgG1 HRP-conjugated goat 1:1000 Serotec 
 
Coomassie blue staining 
In order to control equal loading and protein transfer, gels were stained with 
Coomassie blue staining solution after blotting. Gels were incubated in staining 
solution for 15 minutes and thereafter washed in destaining solution until protein 
bands were clearly visible.  
Ponceau staining 
Membranes were stained with Ponceau to ensure that proteins were evenly 
transferred. Briefly, membranes were incubated with Ponceau staining solution 
for 5 minutes and subsequently washed with demineralised water until protein 
bands were clearly visible. For removing the coloring the membrane was 
washed 4 times for 5 minutes with TBS-T. 
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5 Immunoprecipitation 
5.1 Principle 
Immunoprecipitation is used for the enrichment of certain proteins from cell 
lysates as well as for investigation of protein-protein interaction. Frequently, it is 
applied for the analysis of receptor tyrosine kinases and their scaffold or 
adaptor proteins, also referred to as co-immunoprecipitation. For that, 
antibodies specific for one protein of interest are added to the whole cell 
lysates. After formation of the antigen-antibody complex, this complex is 
precipitated with protein A, a bacterial protein (from Staphylococcus aureus) 
bound to agarose beads with high affinity to the Fc moiety of immunoglobulins. 
After purification of the immunoglobulin loaded beads, the immune complex is 
dissociated and the protein with its ligands is analyzed by Western blot. 
5.2 Experimental procedure 
Cells were treated and harvested as described under 4.2 unto protein 
determination. After the determination of the protein concentration, equal 
amounts (300 – 400 µg) of proteins were aliquoted and filled up to a final 
volume of 500 µl with lysis buffer. Afterwards the corresponding volume of the 
respective antibody was added to the lysates, according to the manufacturer’s 
instruction and rocked gently overnight. For each sample, 50 µl of a 50 % 
solution of Protein A, immobilized on agarose beads, were centrifuged shortly, 
the supernatant was removed and the beads were resuspended in the 
adequate volume of lysis buffer. 50 µl of this suspension was added to each 
lysate und swayed gently for 3 hours. After this time, the bead solutions were 
centrifuged (10,000 x g, 5 minutes, 4°C), 40µl of the supernatant were kept as 
binding control and the beads were carefully washed three times with lysis 
buffer with a short run centrifugation after each washing step. Subsequently the 
wash solution was removed completely by centrifugation (10,000 x g, 5 minutes, 
4°C), sample buffer containing β-mercaptoethanol was added to the pellet and 
the probe was heated to 95°C for 5 minutes to dissolve the protein from the 
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precipitate. After recentrifugation (10,000 x g, 30 seconds, 4° C), 30µl of each 
supernatant were analyzed via Western blot as described under 3. 
6 Cell cycle analysis 
6.1 Flow cytometry 
6.1.1 Principle 
Flow cytometry is a means of measuring certain physical and chemical 
characteristics of cells or particles as they travel in suspension one by one past 
a sensing point. To achieve a flow of cell one after another through a small 
capillary without blocking it, a combination of two physical phenomena is used. 
1) Assuming a laminar flow of liquid through a tube, a viscous drag at the 
boundary will result in a higher velocity in the centre. The velocity profile 
resembles a parabola. The Bernoulli Effect associates these changes in speed 
with inverse alterations in pressure, such that any particle in the fluid will move 
toward and remain in the centre. 
2) In order to prevent blocking, a suspension of cells is introduced through a 
wide test tube which is surrounded concentrically by a larger tube containing a 
sheath fluid. By constricting of this coaxial flow whilst maintaining a laminar flow 
a focused stream of cells is obtained (figure 7). 
Direction of flow
Velocity gradient
Lower pressure
Sheath fluid
The Bernoulli Effect
Hydrodynamic focusing
 
Figure 7: Fluidics and hydrodynamic focusing. 
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As stated above, flow cytometers are configured to examine several parameters 
of cells or particles simultaneously. To get these information the cells are 
exposed to a laser beam. As a cell passes through this laser beam several 
physical processes take place: 
- absorption, diffraction, refraction and reflection of the incident light and 
- emission of longer wavelengths following excitation and relaxation of 
electronic states (fluorescence) 
Diffraction has an impact close to the optical axis and is closely related to the 
size of the object. This low angle scattered light represents an important 
parameter commonly referred to as “forward angle light scatter” (FSC). At 
higher angles, refraction and reflection become more and more important. 
These effects are caused by structural features of the cell, such as granularity 
and surface winding. These parameters are measured orthogonal to the stream 
and are referred to as “side scatter” (SSC). In adition fluorescence is also 
measured in an angle of 90° to the laser beam after separating various 
components by optical filtration. Figure 8 shows a typical arrangement for 
measurement of four components. 
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Figure 8: Basic optics of a flow cytometer. 
6.1.2 Propidium iodide staining (Nicoletti) 
Principle 
Propidium iodide (PI) binds to DNA or RNA by intercalating between the bases 
with a stoichiometry of one per 4-5 base pairs (Waring, 1965). It can therefore 
be used to quantify the cell’s DNA content. After binding to nucleic acids, its 
fluorescent characteristics are changed. Fluorescence is enhanced 20- to 
30-fold, its excitation maximum is shifted approximately 40 nm to the red and 
the fluorescence emission maximum is shifted approximately 15 nm to the blue 
(Arndt-Jovin and Jovin, 1989). PI is membrane impermeable and generally 
excluded from viable cells. Thus, in order to determine the DNA content of 
C Materials and Methods 52 
viable cells they have to be permeabilized using a specific PI-staining solution 
(HFS buffer). 
 
Solutions 
HFS Buffer 
Propidium iodide 50.0 µg 
Sodium citrate  0.1% (w/v) 
Triton X-100  0.1% (v/v) 
PBS  ad 1000.0 µl 
FACS buffer 
Na-azide   0.20 g 
KH2PO4   0.26 g 
KCl   0.28 g 
Na2EDTA   0.36 g 
LiCl   0.43 g 
Na2HPO4   2.35 g 
NaCl   8.12 g 
H2O  ad 1000 ml, pH 7.37 
 
Experimental procedure 
Cells were seeded with 50,000 cell/well in 6-well plates and kept in growth 
medium for 24 hours. Before stimulation, cells were serum-starved for four days 
to ensure synchronization in G0-phase of the cell cycle.  
For cell cycle analysis, cells were treated with 10% bovine serum or PDGF 
20 ng/ml for different periods of time. CAPE was preincubated 30 min before 
stimulation with either serum or PDGF. After 48 hours, cells were trypsinized, 
washed once with PBS and resuspended in 500 µl PI-staining solution. After 
incubation in the dark at 4°C overnight, PI-stained nuclei were analyzed with a 
FACSCalibur (BD Biosciences). 
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6.1.3 BrdU/7-amino-actinomycin D (7-AAD) co-staining 
Principle 
After adding bromodeoxyuridine (BrdU) to the medium, it is incorporated in 
newly synthesized DNA instead of its analogue thymidine. Immunofluorescent 
staining of BrdU with specific FITC-labeled anti-BrdU fluorescent antibodies is 
used to determine the frequency and nature of individual cells that have 
synthesized DNA. Combining the immunofluorescent staining with applying a 
dye that binds to total DNA such as 7-AAD, permits the enumeration and 
characterization of cells that are actively synthesizing DNA (BrdU incorporation) 
in terms of their cell cycle position (defined by 7-AAD staining intensities). 
Prolonged exposure of cells to BrdU allows for the identification and analysis of 
actively-cycling, as opposed to non-cycling, cell fractions. Pulse labeling of cells 
with BrdU at various time points, permits a detailed examination of cell-cycle 
kinetics. 7-amino-actinomycin D is used for determination of DNA content 
instead of PI in these experiments as the wavelengths of light emitted by 7-AAD 
and FITC does not overlap and can thus be analyzed in distinct channels. 
Experimental procedure 
Cells were seeded with 80,000 cells/well in 6-well plates and kept in growth 
medium for 24 hours. Before stimulation, cells were serum-starved for four days 
to ensure synchronization in G0-phase of the cell cycle.  
Cells were treated with 10% bovine serum for different periods of time. CAPE 
was preincubated 30 min before stimulation with either serum or PDGF. After 4 
hours, 1 µM aphidicolin was added and cells were grown for another 15 hours 
in the presence of aphidicolin and 10% calf serum to achieve G1/S-phase 
arrest. Subsequently, aphidicolin was removed by washing cells once with PBS 
before adding fresh growth medium containing 2 µM aphidicolin, 50 µM CAPE 
or vehicle for another 4 hours. For the last 30 minutes of incubation, cells were 
pulse labeled with 10µM BrdU, harvested and processed as described by the 
manufacturer (BrdU Flow Kit, BD Biosciences). Briefly, cells were fixed and 
permeabilized using buffers provided by the kit, followed by treatment with 
DNAse to expose BrdU epitopes. These were labeled using FITC-conjugated 
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anti-BrdU specific antibodies. Additionally, total DNA was stained with 7-AAD as 
described by the manufacturer. Analysis was performed with a FACSCalibur 
(BD Biosciences). 
6.2 3H-thymidine incorporation 
6.2.1 Principle 
A second means to determine cells synthesizing DNA is the 3H-thymidine 
incorporation. After adding radioactively labeled thymidine to the medium it is 
incorporated in newly synthesized DNA which becomes radioactive. 
Radioactive isotopes of hydrogen cannot be detected directly but by interaction 
of their radiation with the surrounding material. Due to its low energy content the 
β-radiation of 3H-thymidine can not be measured by Geiger counters or similar 
devices but by using liquid scintillation counting (LSC). LSC is based on few 
well understood physical phenomena. The radioactive probe is dispensed 
homogenously in scintillation liquid. The kinetic energy is transformed into 
photons by exciting an appropriate fluorophore contained in the scintillation 
liquid. These photons are then converted into an electric pulse by a photovoltaic 
element. One of the major advantages of this method is the radioactive emitter 
being solved in the scintillation cocktail. The radiation can excite both the 
molecules of the solvent and the fluorophore. The molecules of the solvent in 
turn are able to transfer their energy to the fluorophore, too. Thereby the energy 
of the emitted radiation is transferred with almost 100 % to the fluorophore and 
no energy is lost in the transfer from emitter to scintillator. The total amount of 
excited fluorophores depends on the kinetic energy of the radioactive particle. 
The total quantity of photons generated is referred to as scintillation. 
6.2.2 Experimental procedure 
To measure DNA synthesis, VSMCs grown in 6-well plates were made 
quiescent for 48 hours in DMEM without calf serum. After pre-treatment with 
vehicle, CAPE or SB203580 at the indicated concentrations for 30 minutes, 
cells were treated with 20 ng/ml PDGF for 18 hours. Then 
2 µCi/ml methyl-3H-thymidine (Amersham, Biosciences, Freiburg, Germany) 
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were added, cells were pulse labeled for another 6 hours and the amount of 
incorporated 3H-thymidine was assessed. In few words, cells were washed 
twice with ice-cold PBS and incubated with ice-cold 5% trichloracetic acid for 15 
minutes at 4°C. After washing with 70% ethanol, the wells were dried. Then the 
cells were dissolved in 0.5 ml of 0.4 M NaOH for 15 minutes at room 
temperature. 0.4 ml of the NaOH solution were added to scintillation vials 
containing 0.2 ml of 1 N HCl. After adding 5 ml Liquiscint (Roth), the samples 
were analyzed in an LS 6500 Beckman Coulter (Beckman, Krefeld, Germany).  
7 Microscopy 
7.1 Confocal laser scanning microscopy (CLSM) 
7.1.1 Principle 
CLSM offers a higher optical resolution compared to conventional microscopy 
(figure 9). There are two major advantages. first, by a pinhole sitting conjugated 
to the optical plane (i.e. confocal) out-of-focus blurs are eliminated and the 
selectivity of the image is enhanced. Second, by using a laser it is possible to 
assemble a high resolution picture by scanning the sample sequentially, point 
by point with several information of every single pixel. 
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Figure 9: Principle of confocal laser scanning microscopy 
7.1.2 Solutions 
Fixative 
Paraformaldehyde 4 g 
PBS ad 100 ml 
Dissolve paraformaldehyde by stirring and heating (max. 70°C) in a fume hood. 
After adding 1-2 drops of 1 N NaOH the solution was filtered and cooled down 
before use. The solution was freshly made before each experiment. 
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Blocking buffer 
BSA  3 g 
PBS ad 100 ml 
 
Quenching solution 
NH4C  0.078 g 
PBS ad  30.0 ml 
7.1.3 Experimental procedure 
Glass cover slips (∅ 12 mm) were prepared in 24-well plates. VSMC or mutant 
NIH 3T3 fibroblasts were grown to 50 % confluence and were treated as 
indicated in Results. After stimulation cells were washed twice with PBS and 
were fixed with fixative for 10 minutes at room temperature. Then cells were 
washed three times for 5 minutes and potential traces of paraformaldehyde 
were quenched with quenching solution for 10 minutes. Afterwards, the cells 
were rinsed once with PBS and then blocked for 1 hour with blocking buffer. 
Thereafter, the blocking buffer was removed and the appropriate primary 
antibody (table 4) was incubated for one hour. After the expiration of this time 
the cells were washed three times with PBS for 5 minutes and then the 
corresponding secondary antibody (table 5) was incubated for another hour. 
Finally, the cells were washed twice with PBS and once with PBS containing 
5µg/ml Hoechst 33342, a fluorescent dye which intercalates between the DNA-
strands, in order to stain the nucleus.  
 
Table 4: primary antibodies 
Target Source Dilution Provider 
Gab1 rabbit 1:100 Cell Signaling 
PI3K-p85 N-SH2 mouse 1:100 Upstate 
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Table 5: secondary antibodies 
Target Source Dilution Provider 
mouse IgG Alexa Fluor 633 
(highly cross-absorbed) 
Goat 1:400 Invitrogen 
rabbit IgG Alexa Fluor 488 Goat 1:400 Invitrogen 
8 Luciferase reporter gene assay 
8.1 Principle 
The activity of a promoter can be determined by a reporter gene assay. The 
promoter to be investigated, or a part of it, is inserted into a plasmid before a 
gene whose product can easily be both detected and quantified. The amount of 
protein synthesized by the transfected cell is dependent on the activity of the 
promoter. In our experiments we used firefly luciferase (from Photinus pyralis) 
under the control of the NF-κB promoter. Luciferase catalyzes the oxidation of 
luciferin to oxyluciferin using ATP and Mg2+ as co-substrates thereby emitting a 
photon (figure 10). This emission of light can be measured. 
Firefly luciferase
Mg2+
+ ATP + O2
Luciferin
+ AMP + PPi+ CO2 + photon
Oxyluciferin
N
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Figure 10: Luciferase catalyzed luminescence reaction 
For normalization, cells are co-transfected with the gene encoding 
β-galactosidase. This E.coli-derived enzyme catalyzes the cleavage of the 
synthetic substrate chlorophenolred-β-D-galactopyranoside (CPRG) releasing 
chlorophenolred which is measured by spectrophotometry. 
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8.2 Transfection of HEK 293 cells 
For the reporter gene assay human embryonic kidney 293 (HEK 293) cells were 
transiently transfected by using the calcium phosphate co-precipitation method 
originally described by Graham et al. (Graham and van der Eb, 1973) and 
modified by Jordan et al. (Jordan et al., 1996) for the transfection of HEK 293 
cells. By presenting the nucleic acid of the plasmids as a co-precipitate of 
calcium phosphate and DNA in the presence of salmon sperm, the uptake by 
cells grown in culture is significantly increased. After entering the cell by 
endocytosis, some of the co-precipitates escape from endosomes or lysosomes 
and enter the cytoplasm and are subsequently transferred to the nucleus. In 
order to check if the used method results in a transfection at all, the cells were 
firstly transfected with pEGFP-N1, a plasmid encoding for green fluorescent 
protein. This protein can easily be detected by fluorescent microscopy thus 
transfected cells can be determined in an easy way. 
The ratio of cells transiently transfected with the gene varies from cell type to 
cell type and can reach up to 50%. The HEK cells were co-transfected with the 
luciferase reporter construct pNF-κB-Luc and the β-galactosidase gene 
pSV-β-Gal. The pSV-β-Gal plasmid contains the Simian virus 40 (SV40) 
promoter driving this gene. In order to exclude interactions between different 
plasmids, control cells were transfected with pNF-κB-Luc, pSV-β-Gal or salmon 
sperm alone. As positive control, the cells were co-transfected with 
pNF-κB-Luc, pSV-β-Gal, salmon sperm and pFC-MEKK. The latter encodes for 
MEKK which eventually results in NF-κB activation. 
Table 6: List of Plasmids 
name promoter reporter gene 
pNF-κB-Luc NF-κB (5x) firefly-luciferase 
pFC-MEKK CMV MEKK 
pEGFP-N1 CMV green fluorescent protein 
pSV-β-Gal SV40 lacZ 
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8.3 Solutions 
Z-buffer 
Na2HPO4 60 mM 
NaH2PO4 40 mM 
KCl  10 mM 
MgCl2  10 mM 
Substrate solution 
CPRG (50 mM) 100 µl 
β-mercaptoethanol 10 µl 
Z-buffer 10 ml 
 
8.4 Experimental procedure 
Cells were pre-incubated for 30 minutes with the indicated substances and 
subsequently stimulated with 1 ng/ml TNF-α for 6h. Then the cells were washed 
with PBS⊕ and lysed with the provided passive lysis buffer (Promega, 
Heidelberg, Germany). To ensure complete and equal coverage of the cells with 
the lysis buffer, the plates were placed on a rocking platform for 15 minutes at 
room temperature and frozen at -80°C until measurement. NF-κB activity was 
measured by the luciferase assay system (Promega, Heidelberg, Germany), 
according to the manufacturers description, with an AutoLumat Plus (Berthold, 
Pforzheim, Germany). Galactosidase activity was assayed by adding the 
substrate solution to 10 µl of each sample and measuring the absorbance at 
550 nm at 37°C in a SpectraFluor Plus microplate reader (Tecan, Crailsheim, 
Germany). 
9 Electrophoretic mobility shift assay (EMSA) 
9.1 Principle 
The interaction of proteins with DNA is crucial for many cellular processes 
including regulation of transcription. One established technique to study gene 
regulation and determining protein-DNA interactions is the electrophoretic 
mobility shift assay (EMSA). Nuclear extracts, containing the protein of interest, 
(here the transcription factor NF-κB) are incubated with linear DNA fragments 
consisting of the corresponding binding sequence. The principle of the EMSA is 
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based upon the fact that protein-DNA complexes migrate more slowly than free 
DNA when subjected to non-denaturing polyacrylamide gel electrophoresis. 
9.2 Extraction of nuclear protein 
Solutions: 
Buffer A 
HEPES (pH 7.9) 10.0 mM 
KCl  10.0 mM 
EDTA  0.1 mM 
EGTA  0.1 mM 
DTT  1.0 mM 
PMSF  0.5 mM 
Complete® 1.0 % 
Buffer B 
HEPES (pH 7.9) 20.0 mM 
NaCl 400.0 mM 
EDTA 1.0 mM 
EGTA 0.5 mM 
Glycerol 25.0 % 
DTT 1.0 mM 
PMSF 1.0 mM 
Complete® 2.0 % 
 
9.3 Experimental procedure 
VSMCs were grown in 6-well plates. After pre-incubation with vehicle or CAPE 
for 30 minutes at the indicated concentrations, cells were treated with 10 ng/ml 
TNF-α for the denoted time. Thereafter, nuclear extracts were prepared as 
described by Schreiber et al. (Schreiber et al., 1989) as follows: cells were 
washed with ice-cold PBS, scraped off in PBS with a rubber cell scraper, 
centrifuged, and resuspended in ice-cold hypotonic buffer A. Cells were 
incubated for 15 minutes. NP40 (10 %, 25 µl) was added to the cells followed 
by 10 seconds of vigorous vortexing and centrifugation of the homogenate at 
14,000 g for 30 seconds. The supernatant, containing the cytosolic proteins, 
was removed. The nuclear pellet was resuspended by forceful shaking for 15 
minutes at 4°C in hypertonic buffer B. The resulting nuclear extract was 
centrifuged at 14,000 g for 5 minutes and the supernatant containing nuclear 
proteins was frozen at -80°C. The protein concentrations were determined by 
the method of Bradford (Bradford, 1976). 
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9.4 Radioactive labelling of oligonucleotides 
STE buffer (pH 7.5) 
Tris-HCl 10 mM 
NaCl 100 mM 
EDTA 1 mM 
9.4.1 Experimental procedure 
Double-stranded oligonucleotide probes containing the consensus sequence for 
NF-κB (5’-AGTTGAGGGGACTTTCCCAGGC-3’) were 5’-end-labeled with 
adenosine 5’-[γ-32P] triphosphate (3000 Ci/mmol) (Amersham, Freiburg, 
Germany) by using the T4 polynucleotide kinase (PNK) (USB, Cleveland, USA), 
which catalyzes the transfer of the terminal phosphate of ATP to the 5’-hydroxyl 
termini of DNA. The oligonucleotides were incubated with T4 PNK for 10 min at 
37°C and the reaction was stopped by adding EDTA-solution (0.5 M). The 
radiolabeled DNA was separated from unlabeled remnants by using NucTrap 
probe purification columns (Stratagene, La Jolla, USA). Radiolabeled DNA was 
eluated from the column by STE buffer. 
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9.5 Binding reaction and electrophoretic separation 
Solutions 
Binding buffer (5x) (pH7.5) 
Glycerol  20.0% 
MgCl2   5.0 mM 
EDTA   2.5 mM 
NaCl   250.0 mM 
Tris-HCl  50.0 mM 
 
Reaction buffer 
DTT   2.6 mM 
Binding buffer (5x) 90.0 % 
Loading buffer 10 % 
 
Non-denaturing PAA-gel (4.5%) 
TBE (10x) 5.30 % 
Rotiphorese® Gel 30 15.80 % 
Glycerol 2.60 % 
TEMED 0.05 % 
APS 0.08 % 
 
Loading buffer (pH7.5) 
Tris-HCl 250.0 mM 
Bromophenol blue 0.2 % 
Glycerol 40.0 % 
 
TBE buffer (10x) (pH 8.3) 
Tris 0.89 M 
Boric acid 0.89 M 
EDTA 0.02 M 
9.5.1 Experimental procedure 
Equal amounts of nuclear protein were incubated for 5 minutes at room 
temperature (RT) in a total volume of 14 µl containing 2 µg poly(dIdC) and 3 µl 
reaction buffer. Subsequently, 1 µl of the radiolabeled oligonucleotide probe 
(approx. 300,000 cpm) was added. After incubation for 30 minutes (RT), the 
nucleoprotein-oligonucleotide complexes were separated by electrophoresis 
(Mini-Protean 3, Bio-Rad, Munich, Germany) on non-denaturing polyacrylamide 
gels (4.5 %). TBE was used as electrophoresis buffer. Bands were visualized by 
applying the gels to Cyclone Storage Phosphor Screens (Canberra-Packard, 
Dreieich, Germany) and analysis was perormed on a phosphor imager (Cyclone 
Storage Phosphor System, Canberra-Packard, Dreieich, Germany). 
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10 1H-Nuclear magnetic resonance (NMR) spectroscopy 
10.1 Principle 
The stability of a molecule is crucial for its biological function. CAPE is an 
unsaturated ester which can exist in two different isoforms. For all experiments 
it must be assured that the same isoform is used. NMR spectroscopy is one 
means to investigate potential changes in a molecule and to ensure a high 
purity. In this method the behavior of protons is observed. The chemical shift, 
i.e. the position of the signal in the spectrum, depends on how the proton is 
bound. The area under the corresponding signal is proportional to the number 
of protons interacting. The influence of adjacent protons can cause a splitting of 
the signal, referred to as spin coupling. By interpreting the chemical shift 
together with the area and a potential spin coupling effect, information of the 
properties and arrangement of the protons within the molecule can be obtained. 
10.2 Experimental procedure 
8 mg of CAPE were dissolved in 650 µl of water-free D6-DMSO. The sample 
was transferred to an NMR-tube, measured and then frozen at -20 °C. Once a 
week, the probe was unfrozen and measured again. After 10 weeks, the 
solution was brought into sunlight for 1 hour and measured a last time as a 
positive control. 
11 Cytotoxicity assays 
In order to exclude that the observed effects are not due to cytotoxicity, 
experiments were performed to ensure that no toxicity was shown in the 
concentrations used. 
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11.1 Propidium iodide exclusion assay 
11.1.1 Principle 
Propidium iodide (PI) is a fluorophore which intercalates into DNA (see also 
chapter 6.1.2). When bound to nucleic acids, the absorption maximum for PI is 
535 nm and the fluorescence emission maximum is 617 nm. PI can be excited 
with a xenon or mercury-arc lamp or with the 488 nm line of an argon-ion laser. 
Healthy cells with an intact membrane are not able to take up the dye while PI 
permeates membranes of dead cells. Hence, it is possible to distinguish viable 
from dead cells, which show an increased fluorescence signal. 
11.1.2 Experimental procedure: 
Cells grown in 6-well plates were serum-starved for 24 hours and treated with or 
without various concentrations of CAPE for 48 hours in the presence of 10 % 
calf serum. Cells were trypsinized, washed once with PBS and resuspended in 
500 µl of PI solution. After incubation on ice in the dark, cells were analyzed by 
flow cytometry using the FL2 detector (FACSCalibur, BD Biosciences, 
Heidelberg, Germany). 
PI solution 
PI  2.5 µg 
PBS ad 1.0 ml 
11.2 Trypan blue exclusion assay 
11.2.1 Principle 
The trypan blue exclusion assay is based on the same principle as the 
PI exclusion assay, except that the test is not based on DNA staining. Due to 
increased permeability of the membranes of dead cells, they can be stained 
with trypan blue and thus be differentiated from viable cells. 
11.2.2 Experimental procedure 
Cells grown in 6-well plates were serum-starved for 24 hours and treated with or 
without various concentrations of CAPE for 48 hours in the absence of calf 
C Materials and Methods 66 
serum. Cells were trypsinized and analyzed in a Vi-Cell™ (Beckman Coulter, 
Krefeld, Germany) 
12 Statistics 
All experiments were performed at least three times. Results are expressed as 
mean ± standard error mean (S.E.M). Statistical analysis was performed by 
analysis of variance (ANOVA) followed by a Bonferroni multiple comparison test 
using Prism version 3.03 for Windows (GraphPad Software Inc., San Diego, 
USA) unless stated otherwise. P values <0.05 were considered significant. 
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D RESULTS
1 Influence of resveratrol on angiotensin II and EGF-treated 
VSMCs 
In order to explain why the following experiments in this chapter have been 
performed, a brief review of our group's work will be given. Haider et al. have 
shown that RV is capable of reducing phosphorylation of Akt dose dependently. 
Further investigation of the pathway revealed that RV acts most likely via 
inhibition of PI3K to reduce Akt activation (Haider et al., 2002). As described in 
chapter B 11.2 PI3K activation occurs by translocation to the plasma membrane 
by recruiting the SH2 domain of the p85 subunit to activated RTKs. Therefore, 
the signaling pathway of RTK transactivation and subsequent Akt activation was 
first investigated. 
Experiments represented from D 1.1 to 1.4 were performed by Dr. Ursula 
Haider (Haider et al., 2005). Experiment D 1.9 was performed by the group of B. 
Neel (Haider et al., 2005). Since these results are important to understand the 
data generated within this thesis, they are implicated in the present work.  
1.1 Resveratrol does not interfere with EGF-R transactivation. 
To confirm previous observations showing that Ang II transactivates the EGF-R 
(Saito and Berk, 2001), we treated VSMCs with Ang II for various times and 
determined EGF-R tyrosine phosphorylation. Ang II caused a rapid increase in 
EGF-R phosphorylation that remained above baseline for 10 min (data not 
shown). We hypothesized that RV may interfere with this process. Agents 
previously described to act as inhibitors of transactivation (the antioxidant NAC, 
PP1, an inhibitor of c-Src kinase and the tyrphostin AG 1478, an inhibitor of 
EGF-R kinase) were used as positive controls. Figure 11 clearly shows that in 
contrast to NAC, PP1 and AG 1478, RV, at a concentration previously shown to 
inhibit Akt activation (Haider et al., 2002), and figure 12A), does not influence 
Ang II-induced EGF-R transactivation. 
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Figure 11. AG 1478, PP1 and NAC, but not RV, attenuate Ang II-induced EGF-R 
phosphorylation. VSMCs were preincubated with A, 250 nM AG 1478 (AG), B, 20 µM PP1, C, 
10 mM NAC or D, 50 µM RV for 30 min before treatment with (+) or without (-) 100 nM Ang II for 
2 min. Lysates were immunoprecipitated (IP) with anti-EGF-R antibody, followed by 
immunoblotting (IB) with anti-phospho-tyrosine (Tyr-P, top panel) or anti-EGF-R antibody (lower 
panel). Panels show one representative western blot out of three (Haider et al., 2005). 
1.2 Transactivation of EGF-R is important for Akt phosphorylation 
Transactivation of the EGF-R has been shown to be essential for Akt activation 
by Ang II (Ushio-Fukai et al., 2001b; Eguchi et al., 1999b). To confirm that 
transactivation is indeed implicated in Akt phosphorylation in our cells, we 
treated VSMCs with AG 1478 prior to stimulation. The substance markedly 
decreased Akt phosphorylation (figure 12B), but failed to completely abolish the 
signal. These data indicate that EGF-R is indeed important for Ang II-induced 
Akt phosphorylation, although, to a smaller extent, parallel pathways should be 
considered. 
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Figure 12. Effect of RV and AG 1478 on Ang II-induced Akt phosphorylation. VSMCs 
were preincubated with A, 50 µM RV, B, 250 nM AG 1478 (AG) or vehicle for 30 min before 
treatment with (+) or without (-) 100 nM Ang II for 10 min. Lysates were immunoblotted with 
anti-phospho-Akt (Ser473, top panels) or anti-Akt antibody (lower panels). Graphs at the 
bottom show mean ± SE from three independent experiments, expressed as inhibition of
Ang II-induced Akt phosphorylation. **P<0.01 vs. Ang II; ***P<0.001 vs. Ang II (one-sample 
t test) (Haider et al., 2005). 
1.3 RV inhibits EGF-induced Akt phosphorylation 
Since EGF-R transactivation is not impeded by RV, we assumed this substance 
to influence pathways downstream of the EGF-R. Consequently, we tested 
whether RV was also effective in blocking Akt phosphorylation when EGF 
instead of Ang II is used for stimulation. EGF rapidly stimulated Akt 
phosphorylation with a peak at 2 min (figure 13A). Figure 13B shows that RV as 
well as PP1, AG 1478 and wortmannin used as positive controls strongly 
inhibited EGF-induced Akt phosphorylation, suggesting that RV indeed 
interferes with pathways downstream of the EGF-R. 
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Figure 13. Effect of RV, AG 1478, PP1 and wortmannin on EGF-induced Akt 
phosphorylation. A, time course of EGF-induced Akt phosphorylation. VSMCs were treated 
with 100 ng/ml EGF for the indicated times. Lysates were immunoblotted with anti-phospho-Akt 
(Ser473, top panel) or anti-Akt antibody (lower panel). Graph at the bottom shows mean ± SE 
from three independent experiments, expressed as fold increase over control. *P<0.05 
(ANOVA/Dunnett). B, VSMCs were preincubated with vehicle, 50 µM RV, 20 µM PP1, 250 nM 
AG 1478 (AG), or 50 nM wortmannin (WM) for 30 min before treatment with (+) or without (-) 
100 ng/ml EGF for 4 min. Lysates were immunoblotted with anti-phospho-Akt (Ser473, top 
panel) or anti-Akt antibody (lower panel). Graph at the bottom shows averaged data, expressed 
as inhibition of EGF-induced phosphorylation. Values are mean ± S.E.M. from four independent 
experiments. **P<0.01 vs. EGF; ***P<0.001 vs. EGF (one-sample t test) (Haider et al., 2005). 
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1.4 RV acts upstream of PI3K activation 
PI3K is essential for Akt activation in both receptor tyrosine kinase- as well as G 
protein-coupled receptor-triggered pathways (Datta et al., 1999). Ang II strongly 
activates PI3K activity in VSMCs, with concomitant phosphorylation of the 
kinase`s regulatory p85 subunit (Saward and Zahradka, 1997). Our group has 
previously shown that RV attenuates Ang II-stimulated tyrosine phosphorylation 
of the p85 subunit (Haider et al., 2002). In contrast to wortmannin, however 
(figure 14A), RV failed to inhibit Akt phosphorylation upon calf serum stimulation 
(figure 14B). Taken together, these results argue against direct inhibition of 
PI3K activity by RV as shown for wortmannin (Wymann et al., 1996). 
B Akt
[pS473]
Akt
CS
RV
- + +
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A Akt
[pS473]
Akt
CS
Ang II
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- + + - -WM - - + - +
Figure 14. RV and wortmannin differently affect calf serum- and Ang II-induced Akt 
phosphorylation. A, impact of wortmannin (WM) on Ang II- and calf serum (CS)-induced Akt 
phosphorylation. Cells were treated with vehicle or 50 nM WM for 30 min and subsequently 
stimulated with (+) or without (-) CS (30 min) or Ang II (10 min). B, effect of RV on CS-
induced Akt phosphorylation. Cells were treated with vehicle or 50 µM RV for 30 min before 
stimulation with (+) or without (-)10% CS for 30 min. Lysates were immunoblotted with anti-
phospho-Akt (Ser473, top panels) or anti-Akt antibody (bottom panels) (Haider et al., 2005). 1.5 RV decreases phosphorylation of Gab1 and binding of the PI3K p85 
subunit to Gab1 
The adapter molecule Gab1 has recently been shown to be involved in signal 
transduction from the EGF-R to PI3K. In a model proposed by Rodrigues et al., 
Gab1 is first bound to and phosphorylated by the activated EGF-R before its 
interaction with PI3K leads to signal amplification by generation of PIP3. PIP3 
recruits additional Gab1 and, subsequently, PI3K to the plasma membrane 
(Rodrigues et al., 2000). In VSMCs, however, this link has never been 
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established. We therefore investigated whether EGF-stimulation a) enhances 
Gab1 tyrosine phosphorylation (figure 15A) and b) leads to the association of 
Gab1 with the PI3K regulatory p85 subunit (figure 15B). As both Gab1 tyrosine 
phosphorylation and p85-Gab1 association were strongly increased upon 
EGF-stimulation, we tested a possible influence of RV on these processes. 
Most interestingly, RV reduced both, overall Gab1 tyrosine phosphorylation 
(figure 15A) and association of Gab1 and p85 (figure 15B). 
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igure 15. RV decreases phosphorylation of Gab1 and the binding of p85 to Gab1 in
esponse to EGF. A, influence of RV on EGF-induced Gab1 phosphorylation. After pre-
ncubation with 50 µM RV (+) or vehicle (-) for 30 min, cells were stimulated with (+) or without 
-) 100 ng/ml EGF (4 min). Cell lysates were immunoprecipitated with an anti-Gab1 antibody 
nd subsequently immunoblotted with an anti-phospho-tyrosine antibody (upper panel) or anti-
ab1 antibody (lower panel). B, effect of RV on the binding of the regulatory subunit p85 of the 
I3K to Gab1. VSMC were treated and cell lysates immunoprecipitated as described above.
or immunoblot analysis an anti-p85 antibody (top panel) or anti-Gab1 antibody (lower panel) 
as used. One representative western blot out of three is shown. 
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1.6 RV decreases translocation of Gab1 and p85 to the plasma 
membrane 
To confirm the result obtained by immunoprecipitation, we performed 
experiments by confocal microscopy (figure 16). According to the model 
mentioned above, EGF stimulation is associated with recruitment of Gab1 and 
p85 to the plasma membrane (Rodrigues et al., 2000). Figure 16 shows that 
upon stimulation with EGF, both Gab1 and p85 translocate to the membrane. 
This process is potently inhibited when cells are preincubated with RV. 
Importantly, RV alone does not alter the distribution pattern of Gab1 and p85 
compared to vehicle-treated control cells. 
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Figure 16. RV inhibits EGF-induced translocalization of Gab1 and p85 to the plasma 
membrane. VSMC were preincubated with vehicle or 50 µM RV for 30 min and subsequently 
stimulated with or without 100 ng/ml EGF for 4 min. After fixation with 4 % paraformaldehyde, 
cells were co-stained with anti-Gab1 antibody (green channel), anti-p85 antibody (pink channel) 
and Hoechst 33342 (blue channel) and analyzed by confocal microscopy. 
 
D Results 74 
1.7 RV decreases Ang II-induced Gab1 phosphorylation and PI3K p85 
recruitment to Gab1 
Next, we sought to clarify whether also in response to Ang II Gab1 tyrosine 
phosphorylation is increased and the PI3K p85 subunit is recruited to Gab1 in 
VSMC. Figure 17A/B clearly shows that both, Gab1 phosphorylation as well as 
PI3K p85-Gab1 association is stimulated in response to Ang II. RV inhibits both 
signaling events, although Gab1 phosphorylation to a lesser extend than 
p85-Gab1 association (figure 17A/B). 
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igure 17. RV decreases phosphorylation of Gab1 and the binding of p85 to Gab1 in
esponse to Ang II. A, influence of RV on Ang II-induced Gab1 phosphorylation. After pre-
ncubation with 50 µM RV (+) or vehicle (-) for 30 min, cells were stimulated with (+) or without 
-) 100 nM Ang II (4 min). Cell lysates were immunoprecipitated with an anti-Gab1 antibody and 
ubsequently immunoblotted with an anti-phospho-tyrosine antibody (upper panel) or anti-Gab1 
ntibody (lower panel). B, effect of RV on the binding of the regulatory subunit p85 of the PI3K
o Gab1. VSMC were treated and cell lysates immunoprecipitated as described above. For 
mmunoblot analysis an anti-p85 antibody (top panel) or anti-Gab1 antibody (lower panel) was 
sed. One representative western blot out of three is shown. 
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1.8 RV does not inhibit Akt activation in Shp-2-/--cells. 
Recent evidence in fibroblasts revealed a major role for the phospho-tyrosine 
phosphatase Shp-2 in regulating Gab1/PI3K interaction. In these cells, 
inactivation of Shp-2 led to increased phosphorylation of the p85 binding sites 
on Gab1 and increased association of Gab1 and p85 upon EGF-stimulation with 
a subsequent increase in Akt activation (Zhang et al., 2002). We therefore 
hypothesized that RV may act via activation of Shp-2. To verify this hypothesis, 
we used 3T3-immortalized fibroblasts from mice bearing a targeted mutation in 
Shp-2 exon 3 (Shp-2∆46-110, hereafter Shp-2-/-) and Shp-2-/- fibroblasts where 
wild-type Shp-2 expression was restored by retroviral gene transfer at a level 
comparable to that found in wild-type 3T3 fibroblasts (thereafter, controls) 
(Zhang et al., 2002). Western blot analysis revealed that RV did inhibit Akt 
activation upon EGF stimulation in restored control cells (figure 18B). However, 
in Shp-2-/- cells, RV failed to diminish EGF-induced Akt activation (figure 18A). 
Stimulation of Shp-2-/- fibroblasts and reconstituted control cells with Ang II and 
treatment with RV provided virtually the same result (data not shown). These 
data strongly indicate that RV action depends on the presence of functional 
Shp-2. 
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igure 18. RV does not inhibit Akt phosphorylation in a hypomorphic Shp-2 mutant. A, 
T3 fibroblasts expressing hypomorphic mutant of Shp-2 (Shp-2-/-) were treated with vehicle (-) 
r RV (+) for 30 min before stimulation with (+) or without (-) 100 ng/ml EGF for 2 min. Lysates 
ere immunoblotted with anti-phospho-Akt (Ser473, top panel) or anti-Akt antibody (lower 
anel). B, 3T3 fibroblasts, reconstituted with wild-type Shp-2 were treated as described in A. 
*P<0.01 vs. EGF; n.s., not significant (Anova/Dunnett). .9 RV is capable of activating Shp-2 
n order to gain deeper insight into the mechanism by which RV affects Shp-2, 
he Shp-2 activity was assayed in immune complexes from RV-treated cells 
figure 19A) as well as the direct effects of RV on recombinant Shp-2 activity 
figure 19B). RV-treated cells showed a dose-dependent (50 nM-5 µM) increase 
n Shp-2 activity in the presence of EGF, with a maximal stimulation of about 
.5-fold. RV had no statistical effect on Shp-2 activity, when EGF was absent 
figure 19A). RV also induced a smaller (maximum <2-fold), but significant, 
irect dose-dependent increase in phosphatase activity of purified, recombinant 
hp-2 (figure 19B). These data indicate that RV can activate Shp-2 
hosphatase activity, in a dose-dependent manner, both in cell culture and in 
itro. 
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Figure 19 RV activates Shp-2. A, Shp-2 activity was measured in an immune complex 
phosphatase assay using Shp-2 rescue 3T3 fibroblasts. Briefly, Shp-2 reconstituted control cells 
were starved overnight, treated with various concentrations of RV for 30 min, and then 
stimulated with EGF (100 ng/ml) for 5 min. Cells were harvested and lysed in Nonidet P-40 
buffer containing protease inhibitors, but no sodium orthovanadate. Following this lysates were 
immunoprecipitated with Shp-2 antibodies coupled to protein A-Sepharose beads. The amount 
of para-nitrophenyl phosphate (pNPP, Sigma-Aldrich) phosphate released was determined by 
measuring the absorbance at 410 nm. Results are means ± S.E. of the means from triplicate, 
and data were analyzed by a one-tailed paired t test. *, P = 0.04 **, P = 0.002; ***, P = 0.03. RV 
had no statistical significance on Shp-2 activity in the absence of EGF. B, Shp-2 phosphatase 
activity was measured in an in vitro assay using purified recombinant Shp-2 protein (10 nM). 
The rate of hydrolysis of pNPP by Shp-2 was measured in buffer containing various 
concentrations of RV. Results are means ± S.E: of the means from triplicate, and data were 
analyzed by a one-tailed paired t test. *, P = 0.045; **, P = 0.02; ***, P = 0.0003; ****, P = 0.003. 
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2 Influence of CAPE on calf serum- and PDGF-treated VSMCs 
2.1 Stability of CAPE 
CAPE exists in two isomers (figure 20) from which we used trans-CAPE. Its 
conformation can be changed upon light exposure. 
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trans-CAPE cis-CAPE  
Figure 20. CAPE isomers. 
As we used a stock solution of trans-CAPE it was of interest to know whether 
CAPE is stable during usage. In order to confirm its photo stability, CAPE was 
analyzed by 1H-NMR spectroscopy as described in materials and methods. 
Figure A shows the NMR spectrum of freshly solved CAPE, figure B shows 
CAPE after 10 weeks. As can be clearly seen there is no difference between 
the two spectra A and B whereas the spectrum in figure C shows noticeable 
extra peaks resulting from the mixture of the two isoforms. This conformational 
change was achieved by one hour of intensive sunlight exposure to the solution. 
These data confirm that dissolved trans-CAPE is stable during normal usage 
but unstable when exposed to light. 
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Figure 21. trans-CAPE is stable in normal use but alters conformation upon light 
exposure. A, After dissolving of 8 mg CAPE in water-free D6-DMSO the sample was measured 
and then frozen under the same conditions as the working stock (-20 °C). B, after ten weeks 
and ten freeze-thaw cycles the probe was measured again. C, after exposure to sunlight for one 
hour the sample was measured a last time. 
2.2 CAPE dose-dependently inhibits serum-induced VSMC proliferation 
Treatment of VSMCs with different concentrations of CAPE (1-50 µM) caused a 
dose-dependent inhibition of serum-induced (10%) cell proliferation (figure 22). 
Cell number of the serum group increased to about 17 fold compared to 
vehicle-treated control cells after 72 h. CAPE inhibited serum-induced cell 
growth completely at a concentration of 25 µM.  
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Figure 22. VSMC proliferation upon serum-stimulation is inhibited dose-dependently by 
CAPE. After serum withdrawal for 48 h cells were treated with CAPE at the indicated 
concentrations or vehicle for 30 minutes prior to stimulation with 10% serum (+) for 72 h. After 
trypsination, the cell number was assessed by cell counting; unstimulated control values (-) 
were set as 1. The histogram shows the means ±S.E.M of cell numbers compared to serum of 
at least three independent experiments. ***, p < 0.001 versus PDGF (ANOVA/Bonferroni). 
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2.3 CAPE arrests the cell cycle of serum stimulated VSMC in S-phase 
Treatment of serum-stimulated (10%) VSMCs with 50 µM CAPE leads to a cell 
cycle arrest (figure 23). 
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Figure 23. After pre-incubation with vehicle or 5 µM CAPE for 30 minutes, VSMCs were 
stimulated with 10% serum for 24 h. Cell cycle phase distribution was determined by flow 
cytometry after propidium iodide staining of DNA as described in materials and methods. A, 
Representative histograms of flow cytometry are shown. B, Quantification of cells in G0/G1, S 
and G2/M-phase. Results are means ±S.E.M. from three independent experiments. 
In order to confirm this assumption a BrdU incorporation assay as described in 
materials and methods was performed. To synchronize the cells in early S-
phase, aphidicolin was added. Aphidicolin binds directly to DNA polymerase 
and blocks DNA synthesis, while allowing for RNA and protein synthesis and 
progression through G1 (Pedrali-Noy et al., 1980). In accordance with the 
PI-staining assay (figure 23 A), CAPE is capable of inhibiting cell cycle 
progression. The shape of the CAPE dot blot resembles that of aphidicolin, 
hence it is very likely that CAPE arrest the VSMCs in S-phase (figure 24). 
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Figure 24. CAPE causes a cell cycle arrest at G1/S. After synchronization of the cells with 
1 µM aphidicolin for 15 h with, cells were washed once with PBS. Subsequently, fresh growth 
medium containing 2 µM aphidicolin, 50 µM CAPE or vehicle was added for another 4 hours. 
For the last 30 minutes of incubation, cells were pulse labeled with 10µM BrdU, harvested and 
processed as described in material and methods. Representative dot blots of flow cytometry are 
shown. The total DNA content, visualized via 7-AAD, is shown on the x-axis, while newly 
synthesized DNA, visualized via BrdU incorporation, is depicted on the y-axis.  
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2.4 CAPE shows no toxicity on serum-cultured but on serum deprived 
VSMCs 
In order to ensure that the anti-proliferative effects of CAPE are not due to 
cytotoxicity two experiments were performed. First, a PI exclusion assay was 
performed with both serum-treated and serum deprived VSMCs. As shown in 
figure 25 serum-treated cells show no cytotoxic effect of CAPE whereas the 
membranes of serum-deprived cells become PI permeable, an evidence for 
cytotoxicity. 
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D
Figure 25. Serum-deprived VSMCs die upon treatment with 
50 µM CAPE. VSMC were serum-starved for 48 h before 
treated with CAPE at the indicated concentration for another 
48h. Triton-X was added as positive control 10 minutes 
before analysis. After trypsination viable cells were assessed 
by a PI exclusion assay as described in materials and 
methods. One representative histogram of flow cytometry is 
shown. 
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The second experiment, a trypan blue exclusion assay, was performed to 
determine the cytotoxic concentration of CAPE on serum-deprived cells. As can 
be seen in figure 26, only in concentrations higher than 25 µM cytotoxicity of 
CAPE could be observed. 
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Figure 26. Cell viability. VSMC were serum-starved for 48 h before treatement with CAPE at 
the indicated concentration for another 48 h. After trypsination, the viable cell number was 
assessed by cell counting in a trypan blue assay; Control values were set as 100%. The 
histogram shows the means ±S.E.M of cell numbers compared to vehicle-treated cells of at 
least three independent experiments. 
2.5 CAPE dose-dependently inhibits PDGF- induced VSMC proliferation 
Serum is a multi-component stimulus, therefore, it is very difficult to elucidate 
the pathways involved in the before mentioned growth inhibitory effect of CAPE. 
As PDGF-BB is a potent stimulus for VSMC proliferation it was chosen to 
investigate the signaling pathway.  
Treatment of VSMCs with different concentrations of CAPE (1-10 µM) caused a 
dose-dependent inhibition of PDGF-BB (20 ng/ml)-induced cell proliferation 
(figure 27 A). Cell number of the PDGF-group increased to about 1.4 fold 
compared to vehicle-treated control cells after 48 h. CAPE blocked 
PDGF-induced cell growth completely at a concentration of 5 µM. To confirm 
these finding we measured DNA synthesis by 3H-thymidine incorporation. In 
accordance with cell counting results, CAPE (5 µM) was capable to reduce the 
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amount of PDGF-induced thymidine incorporation to almost control levels 
(figure 27 B). 
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Figure 27. CAPE dose-dependently impedes PDGF-induced proliferation of VSMCs. A, 
Cells were treated with vehicle (-), 5 µM SB203580 (+) or CAPE at the indicated concentrations 
for 30 minutes before stimulation with (+) or without (-) 20 ng/ml PDGF-BB for 48 h. After 
trypsination, the cell number was assessed by cell counting; Control values were set as 1. The 
histogram shows the means ± S.E.M of cell numbers compared to PDGF of at least three 
independent experiments. B, VSMCs were pre-treated with vehicle (-), 5 µM CAPE or 5 µM 
SB203580 for 30 minutes, before stimulation with (+) or without (-) 20 ng/ml PDGF-BB for 24 h. 
Thymidine incorporation was assessed as described in materials and methods. The histogram 
shows means of three independent experiments whereas PDGF values were set as 1. *, 
p < 0.05; ***, p < 0.001 versus PDGF (ANOVA/Bonferroni). #, p < 0.05 versus PDGF + CAPE 
(ANOVA/Bonferroni) 
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2.6 Treatment of VSMCs with CAPE results in amplified and sustained 
p38 MAPK activation that contributes to the antiproliferative effect 
Activation of VSMC with PDGF-BB led to induction of several growth-related 
signaling pathways, such as the MAPK (p38, ERK1/2), and the PI3K/Akt 
pathway (figure 28 A) which is in accordance with published data (Zhan et al., 
2003). None of these kinases, however, was inhibited by CAPE at 
concentrations effectively blocking PDGF-induced cell proliferation. In contrast, 
in the presence of PDGF-BB CAPE (5 µM) caused a strengthened and 
prolonged activation of p38 MAPK compared to PDGF-BB alone (figure 
28 B/C). Therefore, we employed the p38 inhibitor SB203580 (5 µM) to see 
whether this sustained activation of p38 can be linked to the antiproliferative 
activity of CAPE. As can be seen in figure 27 A/B, SB203580 indeed partly 
neutralized the inhibitory effect of CAPE indicating that p38 at least contributes 
to the antiproliferative effect of CAPE. 
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Figure 28. PDGF induces several growth-related kinases but CAPE influences only p38 
MAPK. A, Time course of phosphorylation of growth-related kinases p38, Erk1/2, Akt in 
response to PDGF treatment. Cells were treated with PDGF-BB (20 ng/ml) for the indicated 
time and lysed for Western blot analysis as described in materials and methods. B, Influence of 
CAPE on PDGF-induced phosphorylation of p38, Erk1/2, and Akt. After pre-treatment with 5 µM 
CAPE (+) or vehicle (-) for 30 minutes, cells were stimulated with 20 g/ml PDGF-BB for 
10 minutes. Cell lysates were immunoblotted with an anti phospho-p38, anti phospho-Erk1/2, 
and anti phospho-Akt antibody. C, Time course of p38-phosphorylation upon PDGF-BB 
stimulation with or without CAPE pre-incubation. Cell were treated with 5 µM CAPE (+) or 
vehicle (-) for 30 minutes before stimulation with 20 ng/ml PDGF-BB for the indicated time. Cell 
lysates were immunoblotted with an anti phospho-p38 antibody. One representative Western 
Blot out of three is shown, respectively. 
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2.7 CAPE influences cell cycle progression of PDGF-stimulated VSMCs 
In order to specify the antiproliferative effect of CAPE and to additionally 
exclude cytotoxic effects, the cell number in each cell cycle phase was 
determined via flow cytometry (FACS). After exposure of VSMCs to 5 µM CAPE 
in the presence or absence of PDGF-BB for 28 h, FACS analysis showed that 
the proportion of cells in G0/G1-phase increased and the proportion of S- and 
M-phase decreased compared to PDGF-BB-treated cells (figure 29 A/B) 
indicating that CAPE-treated cells tend to accumulate in G0/G1-phase. No 
sub-G1-peak was observed excluding apoptosis induction in response to CAPE. 
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Figure 29. CAPE increases number of cells in G1 phase in PDGF-activated VSMC. After 
pre-incubation with vehicle or 5 µM CAPE for 30 minutes, VSMCs were stimulated with 
PDGF-BB (20 ng/ml) for 28 h. Cell cycle phase distribution was determined by flow cytometry 
after propidium iodide staining of DNA as described in materials and methods. A, 
Representative histograms of flow cytometry are shown. B, Quantification of cells in G0/G1, S 
and G2/M-phase. Results are means ±S.E.M. from three independent experiments. **, p < 0.01; 
***, p < 0.001 versus G0/G1 phase (ANOVA/Bonferroni) 
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2.8 The antiproliferative effect of CAPE is not mediated by NF-κB 
CAPE is a well known inhibitor of the transcription factor NF-κB (Natarajan et 
al., 1996). In addition, NF-κB was shown to regulate cell cycle progression and 
proliferation of a number of cell types, including VSMC, although seemingly 
dependent on the stimulus used (Mehrhof et al., 2005; Selzman et al., 1999). 
We, therefore, tested whether the antiproliferative effect of CAPE might be 
mediated by inhibition of this transcription factor. As demonstrated in figure 
30 A, CAPE (5 µM) was not able to reduce the NF-κB binding activity 
determined by an electrophoretic mobility shift assay (EMSA). Also NF-κB 
transactivation activity was not impaired by 5 µM CAPE as shown by a 
luciferase reporter gene assay (figure 30 B). Altogether, we found that CAPE 
does not inhibit NF-κB at 5 µM but at higher concentrations (50 and 75 µM). 
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Figure 30: CAPE does not affect NF-κB activity at a concentration of 5 µM. A, VSMCs were 
pre-treated with vehicle or CAPE at the indicated concentrations for 30 minutes before 
stimulation with 10 ng/ml TNF-α for 15 minutes. NF-κB binding activity was measured by 
electrophoretic mobility shift assay (EMSA) as described in materials and methods. Data show 
one representative out of three independent experiments from different cell preparations with 
similar results. The histogram shows phosphor imaging analysis of EMSA experiments and 
represents means ±S.E.M.; values of TNF-α treated cells were set as 1. B, Transiently 
transfected HEK 293 cells containing the luciferase reporter construct pNF-κB-Luc and the 
β-galactosidase gene pSV-β-Gal were pre-treated with vehicle or CAPE at the indicated 
concentrations for 30 minutes before stimulation with 10 ng/ml TNF-α. The histogram shows 
luminometer analysis of three independent experiments and represents means ±S.E.M. Values 
of TNF-α treated cells were set as 1.*, p < 0.05; **, p < 0.01; ***, p < 0.001 (ANOVA/Bonferroni). 
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2.9 HO-1 induction by CAPE seems not to be involved in the 
antiproliferative effect 
CAPE is described as a heme oxygenase-1 (HO-1) inducer in astrocytes 
(Scapagnini et al., 2002). In addition, HO-1 is known to lead to cell cycle arrest 
in VSMCs (Choi et al., 2004; Duckers et al., 2001). Moreover, carbon monoxide 
(CO), a product of HO-1 activity was recently shown to mediate its 
antiproliferative effect via p38 activation (Kim et al., 2005). We, therefore, 
investigated whether CAPE induces HO-1 in VSMCs and whether this putative 
induction may contribute to the antiproliferative effect of CAPE in VSMC. As 
shown in Figure 31 A both, cobalt protoporphyrin (CoPP, 10 µM) used as 
positive control and CAPE (5 µM) caused a potent increase in HO-1 expression 
in VSMCs which is not influenced by the p38 inhibitor SB203580. To examine 
whether the antiproliferative effect of CAPE may by due to induction of HO-1, 
we repeated cell counting experiments employing SnPP 10 µM as HO-1 
inhibitor. Figure 31 B indicates that HO-1 does not contribute to the CAPE 
induced cell cycle arrest. 
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Figure 31. CAPE induces HO-1 in VSMCs. A, 
After pre-incubation with 5 µM SB203580 (+) or 
vehicle (-) for 30 minutes, cells were stimulated 
with 5 µM CAPE (+), 10 µM CoPP as positive 
control (+) or left untreated (-) for 12 h. Cell 
lysates were immunoblotted with an anti HO-1 
antibody. One representative Western Blot out of three is shown. B, Inhibition of HO-1 does 
not reduce the growth inhibitory effect of CAPE. VSMCs were synchronized in G0/G1 as 
described in materials and methods After pre-treatment with vehicle (-), 5 µM CAPE (+), 10 µM 
SnPP (+) or with both 5 µM CAPE (+) and 10 µM SnPP (+) for 30 minutes, the cells were 
stimulated with 20 ng/ml PDGF-BB for 48 hours. The histogram shows the means of cell 
number ratio of at least three independent experiments, whereas the PDGF values were set as 
1. **, p < 0.01; ***, p < 0.001 (ANOVA/Bonferroni) 
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2.10  Caveolin-1 is upregulated by CAPE – involvement of p38 
Recently, caveolin-1 has been described as a potent regulator of VSM cell 
signaling pathways, in particular of those resulting in proliferation (Thyberg, 
2003; Hassan et al., 2004). Moreover, caveolin-1 expression was shown to 
occur via p38 activation in PDGF-BB-activated VSMC (Kim et al., 2005). We 
therefore, examined whether CAPE (5 µM) may increase caveolin-1 expression 
in PDGF-BB-activated VSMCs and whether this effect is reversed by the p38 
inhibitor SB203580 (5 µM). Western blot analysis showed that pre-incubation of 
VSMCs with CAPE before stimulation with PDGF-BB could restore the 
PDGF-induced degradation of caveolin-1 (figure 32). This effect was neutralized 
by SB203580. Moreover, anisomycin, an activator of the p38 MAPK pathway, 
was able to mimic the effect of CAPE. 
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Figure 32. CAPE impairs PDGF-induced caveolin-1 degradation. Cells were pre-incubated 
with vehicle (-), 5 µM CAPE (+), 5 µM SB203580 or 10 µM anisomycin as positive control for 30 
minutes, before stimulation with 20 ng/ml PDGF-BB for 12 h. Cell lysates were immunoblotted 
with an anti caveolin-1 antibody. One representative Western Blot out of three is shown. 
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E DISCUSSION 
1 Influence of resveratrol on the signaling pathway in VSMC 
upon Ang II stimulation 
The first part of this thesis provides new insight into the putative molecular 
mechanisms by which RV interferes with Ang II- and EGF-mediated signaling 
pathways in VSMCs. We were able to show that EGF-R transactivation upon 
Ang II stimulation is not inhibited by RV. However, RV potently impairs EGF- as 
well as Ang II-stimulated Akt phosphorylation. The data provided in this work 
strongly suggest that Shp-2, a protein tyrosine phosphatase previously shown 
to be involved in EGF-induced PI3K activation in fibroblasts (Wu et al., 2001), is 
a major part of the involved pathway. Moreover, our data provide evidence that 
in Ang II- or EGF-activated VSMC Gab1 and Shp-2 play the same important 
role as they have been shown for EGF signaling to the PI3K/Akt-pathway in 
fibroblasts. 
Ang II has become apparent as a key player in the pathogenesis of vascular 
diseases. It has been associated with several symptoms of atherosclerosis, 
such as hypertrophy, proliferation and migration of VSMCs as well as in 
inflammation and extracellular matrix deposition. This emphasizes its 
importance for vascular remodeling (Schmidt-Ott et al., 2000). Referring to this, 
it has recently been shown that transactivation of the EGF-R is important for 
early Ang II signaling through the AT1 receptor (Kalmes et al., 2001). Consistent 
with results reported by others (Ushio-Fukai et al., 2001a), we show a rapid 
increase in overall EGF-R phosphorylation upon Ang II stimulation. This 
transactivation was not impaired by RV, indicating that RV acts downstream of 
the EGF-R. Consistently, Akt phosphorylation is inhibited even when VSMCs 
are stimulated with EGF instead of Ang II. 
PP1, a c-Src inhibitor, is capable of completely inhibiting EGF-induced Akt 
phosphorylation, and studies performed in other cell systems suggest that c-Src 
kinase is important for signaling downstream of EGF-R (Sato et al., 1995; 
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Stover et al., 1995). Interestingly, in HeLa cells, RV has been shown to act as 
an inhibitor of c-Src tyrosine kinase (Yu et al., 2001). Although c-Src is 
phosphorylated at various sites, phosphorylation of tyrosine418 in the kinase 
domain is most important, as its autophosphorylation leads to increased kinase 
activity (Abram and Courtneidge, 2000). Our group found that RV does not alter 
phosphorylation of c-Src tyrosine418 (Haider, 2003). We further found that 
EGF-induced phosphorylation of tyrosine845 of the EGF-R, a highly conserved 
site previously shown to be phosphorylated in a c-Src dependent manner 
(Biscardi et al., 1999), is not altered by RV (Haider, 2003). Together with the 
fact that RV, in contrast to the c-Src inhibitor PP1, does not prevent 
Ang II-induced EGF-R transactivation, these data show that c-Src activity is not 
impaired in RV-treated VSMCs. 
Most interestingly, RV was not capable of reducing serum-induced Akt 
phosphorylation, whereas wortmannin, a PI3K-inhibitor that inactivates the 
catalytic subunit of PI3K, was able to inhibit Akt activation. These observations, 
strongly suggest that RV acts upstream of PI3K activation when pathways of 
serum- and Ang II-induced Akt activation have not yet converged. One question 
concerning growth factor signaling is how specificity is achieved by different 
stimuli, as many growth factors use the same adapter molecules and 
downstream effectors. For the EGF-pathway, a positive feedback loop between 
the adapter Gab1 and PI3K has been proposed, where the PI3K participates 
both upstream and downstream of Gab1 (Rodrigues et al., 2000). Referring to 
this, recent work shows that Gab1 and Shp-2 act together in regulating PI3K 
activity. Briefly, Shp-2 diminishes PI3K activation in response to EGF by 
specifically dephosphorylating the p85 binding sites on Gab1, thereby 
interrupting the before mentioned positive feedback loop. Hence, in Shp-2-/- 
cells, association between Gab1 and p85 is enhanced, leading to an increased 
activity of PI3K and Akt (Zhang et al., 2002). Most interestingly, this effect has 
been shown to be specific for EGF since other growth factors such as PDGF or 
IGF-1 did not lead to enhanced Akt activation in Shp-2-/- cells (Zhang et al., 
2002). These results indicate specificity for the EGF-governed pathways. We 
were able to show that stimulation of VSMCs with EGF as well as with Ang II 
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leads to a rapid tyrosine-phosphorylation of Gab1 and subsequent association 
of Gab1 and the p85 subunit of PI3K. Application of RV led to a decreased 
overall Gab1 phosphorylation, and thus p85 association with Gab1. The 
inhibition of Gab1 phosphorylation was not as distinct as the inhibition of p85 
recruitment to Gab1, especially after stimulation with Ang II. These data 
correspond to the observation that Shp-2 specifically dephosphorylates only the 
p85 binding sites on Gab1 (Zhang et al., 2002). Moreover, by confocal 
microscopy we revealed that EGF-induced translocation of Gab1 and p85 to the 
plasma membrane is inhibited by RV. Altogether, these results strongly indicate 
that RV interferes with the association of Gab1 and p85, most likely an early 
stage in the above-mentioned feedback loop. Our results strongly suggest that 
the underlying mechanism is inhibition of Gab1 phosphorylation, raising the 
possibility that Shp-2 may be essential for RV’s mechanism of action. In order to 
clarify the role of Shp-2 in the signaling of RV, we performed experiments using 
Shp-2-/- fibroblasts and, as a control, Shp-2-/- cells where WT-Shp-2 expression 
was restored by retroviral gene transduction. As expected, RV did not prevent 
EGF-induced Akt activation in Shp-2-/- cells, whereas inhibition was highly 
significant in the reconstituted, WT-Shp-2 expressing control cells. These data 
suggest that RV may act via activation of Shp-2. Further experiments, indicated 
that RV is capable of activating Shp-2 in RV-treated cells (in situ) as well as in 
vitro. Given that the maximal stimulation in situ is more dramatic than in vitro, it 
indicates that at least some of the effects of RV are not mediated by direct 
action of RV on Shp-2. In this context, it is interesting that recent studies have 
shown that phospho-tyrosine phosphatases (PTPs), including Shp-2 (Meng et 
al., 2002), are inhibited by peroxide-mediate oxidation of the catalytic cysteine 
residue (reviewed by (Finkel, 2003). Since previous work has suggested that 
RV inhibits NADPH oxidase (Nox) enzymes (Orallo et al., 2002), our 
observations suggest that at least one part of the mechanism of RV may be the 
inhibition of hydrogen peroxide generation via Nox proteins, thus resulting in 
higher levels of catalytically active Shp-2. Given that Gab1 translocates to the 
membrane upon EGF stimulation (figure 16) and Shp-2 binds to Gab1, this may 
bring the phosphatase to the vicinity/proximity of a specific NOX enzyme. 
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Consistent with our observation that RV only affects Shp-2 activity after EGF 
stimulation it has been shown that in the absence of stimulation, Shp-2 exists in 
a closed form in which ROS probably cannot access the active site cysteine 
(reviewed by (Barford and Neel, 1998). In order to test this model as well as to 
clarify the mechanism by which RV is capable of directly stimulating 
recombinant Shp-2, further studies have to be performed.  
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2 Influence of CAPE on the proliferation in VSMC upon 
serum- and PDGF-stimulation 
In the second part of this study, we show that CAPE abolishes both serum and 
PDGF-induced VSMC proliferation. The inhibitory concentration (5 µM) upon 
PDGF-BB stimulation was ten-times below that needed to inhibit NF-κB activity. 
None of the major classical growth promoting signaling pathways (ERK1/2, 
PI3K/Akt) was affected by CAPE. In contrast, we found an enhanced and 
sustained phosphorylation of p38 MAP kinase in response to CAPE contributing 
to its antiproliferative effect. Our study in association with recent published data 
(Kim et al., 2005) strongly suggests that CAPE mediates its effect via a 
HO-1-independent activation of p38 MAPK and a subsequent increased 
expression of caveolin-1 leading to cell cycle arrest at G1 phase.  
VSMCs are known to play a crucial role in the development of atherosclerosis 
and restenosis (Ross, 1999; Newby, 2000). One major autocrine and paracrine 
mitogen for VSMCs mediating atherosclerotic processes such as hyperplasia, 
hypertrophy and migration is PDGF (Scapagnini et al., 2002; Yu et al., 2003; 
Berk, 2001). Maffia et al. have recently shown that CAPE is able to reduce 
restenosis after balloon angioplasty (Maffia et al., 2002). Thus, we hypothesized 
that CAPE is able to inhibit PDGF-BB-induced VSMC proliferation and sought to 
identify the mechanisms of this putative effect.  
CAPE indeed inhibited PDGF-induced VSMC growth dose-dependently 
(1-5 µM). Interestingly, this effect was associated with an increased and 
prolonged phosphorylation of p38 MAPK. The role of p38 MAPK in cell 
proliferation is controversially discussed: activation of p38 MAPK was shown to 
result in cell proliferation in VSMC after vascular injury (Ju et al., 2002). On the 
other hand, some data show that activation of p38 MAPK correlates with 
inhibition of cell cycle progression at G1/S transition (Molnar et al., 1997) and 
that inhibition of p38 MAPK stimulates proliferation (Philips et al., 2000). These 
findings indicate that p38 MAPK is able to differentially regulate cell proliferation 
depending on cell type, stimulus and cell cycle position (Ambrosino and 
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Nebreda, 2001). Prolonged p38 phosphorylation in response to CAPE was not 
only associated with VSM cell cycle arrest but also inhibited by the p38 inhibitor 
SB203580 suggesting that p38 contributes to the growth inhibitory effect of 
CAPE. 
CAPE has been described as a potent NF-κB inhibitor (Natarajan et al., 1996) 
and NF-κB is shown to mediate cell proliferation and cell cycle progression in 
various cell types (Mehrhof et al., 2005). Activation of NF-κB in response to 
PDGF-BB in VSMC, however, is disputed (Mehrhof et al., 2005; Peppel et al., 
2005; Son et al., 2006) We, therefore, decided to monitor NF-κB binding and 
transcriptional activity in response to CAPE in order to see whether NF-κB 
could mediate CAPE-induced cell cycle arrest. In agreement with our results 
data provided by (Natarajan et al., 1996) showed that CAPE acts as NF-κB 
inhibitor only at concentrations higher than 50 µM. Thus, we exclude the 
possibility that CAPE mediates its antiproliferative effect by inhibition of NF-κB. 
Heme oxygenase-1 (HO-1) plays a central role in regulating intracellular heme 
levels by catalyzing the first and rate-limiting step in the degradation of heme 
(Tenhunen et al., 1968) thereby generating carbon monoxide (CO), biliverdin 
and free iron. Inhibition of HO-1 by zinc or tin protoporphyrin IX potentiates the 
mitogenic action of serum, endothelin, angiotensin II and PDGF in VSMCs 
(Choi et al., 2004; Peyton et al., 2002; Durante, 2002; Togane et al., 2000) 
pointing to an antiproliferative effect of HO-1. Further evidence was given by 
Duckers et al. using VSMC from HO-1 knockout mice. These cells exhibited 
enhanced DNA synthesis and proliferation compared to wild type SMCs 
(Duckers et al., 2001). Thus, substantial evidence indicates that HO-1 is a 
negative regulator of growth in VSMCs by means of CO (Durante, 2002; Peyton 
et al., 2002). In addition, CAPE is a potent inducer of HO-1 in astrocytes 
(Scapagnini et al., 2002).The antiproliferative effect of CAPE could, therefore, 
also be mediated by its ability to induce HO-1 (Scapagnini et al., 2002). 
Although we were able to confirm induction of HO-1 by CAPE in VSMCs, the 
antiproliferative effect of CAPE was not affected by HO-1 inhibition suggesting 
that CAPE-induced cell cycle arrest occurs independently of HO-1 induction. 
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Caveolin-1 was discovered in the early 1990s and is a major structural 
component of caveolae, invaginations of the cell membrane contributing to the 
regulation of many cellular processes such as eNOS activity, EGF-R or 
PDGF-R signaling (Schlegel et al., 1998). The role of caveolin-1 in VSMCs has 
not yet fully been characterized, but studies performed by Peterson et al. 
propose an antiproliferative role for this membrane protein, especially upon 
stimulation with PDGF (Peterson et al., 1999; Peterson et al., 2003). In 
agreement with these data a recent study has shown that caveolin-1 negatively 
regulates VSMC proliferation and neointima formation of injured aorta (Hassan 
et al., 2004). Moreover, a recently published study has established a clear link 
between CO, p38 MAPK activation and caveolin-1 up regulation. Herein, they 
show that CO caused p38 phosphorylation which in turn resulted in increased 
caveolin-1 level leading to VSMC growth arrest (Kim et al., 2005). In agreement 
with these data, CAPE led to a strong rise of caveolin-1 in the presence of 
PDGF compared to PDGF alone and the specific p38 inhibitor SB203580 was 
able to reverse this effect. In contrast to published data by Kim et al. (2005), 
however, activation of p38 MAPK did not occur via the HO-1/CO pathway. 
Since the second messenger of CO is cGMP it is conceivable that CAPE 
increases intracellular cGMP levels in VSMC similarly as demonstrated earlier 
for red wine polyphenols (El-Mowafy, 2002; Dell'Agli et al., 2005). Further 
experiments will be necessary to clarify a possible role of cGMP in CAPE 
signaling. 
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F SUMMARY 
1 Effects of resveratrol on the signaling pathway in VSMC 
upon Ang II stimulation 
In this thesis we provide important new insight into the mechanisms by which 
RV interacts with Ang II- and EGF-induced signaling pathways involved in the 
pathogenesis of cardiovascular disease. One of these pathways is the PI3K/Akt 
pathway which was investigated more detailed. We were able to show that 
although EGF-R transactivation is important for Akt activation, RV does not 
interfere with this step. Additional experiments revealed that the most probable 
target of RV lies downstream of EGF-R but upstream of Akt activation. Refering 
to this, it is important to note that we showed for the first time an important and 
specific role for Shp-2 and Gab1 in EGF signaling to the PI3K/Akt pathway in 
VSMCs. Furthermore, we were able to demonstrate that RV decreased binding 
of Gab1 to the PI3K subunit p85 and subsequent translocation of the complex 
to the plasma membrane. Most importantly, we were able to show that Gab1 
phosphorylation and p85 recruitment to Gab1 was also decreased upon Ang II 
stimulation. By continuative analysis we revealed that Shp-2 is responsible for 
the Gab1 dephosphorlyation and that RV seems to be capable of activating 
Shp-2. As this thesis provides new details in early signaling events triggered by 
EGF and Ang II regarding the role of Shp-2 and Gab1, it assists to elucidate the 
molecular mechanisms elicited by RV in VSMCs. Therefore, it may be helpful to 
analyze the suitability of RV as a putative therapeutic or preventive agent in 
cardiovascular disease. 
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Figure 33. Resveratrol acts via the phosphatase Shp-2. The exact target of resveratrol is not 
yet identified. However, Shp-2 is the most upstream target shown to be involved in the depicted 
EGF-R-mediated signaling cascade.  
2 Effects of CAPE on the proliferation of VSMC upon serum- 
and PDGF-stimulation 
In the present work, we have clearly demonstrated that CAPE inhibits both, 
serum and PDGF-induced VSMC proliferation. Effective concentrations upon 
PDGF-BB stimulation were as low as 5 µM. These properties are most likely 
mediated by p38 MAPK phosphorylation and subsequent upregulation of 
caveolin-1. Our study provides first insights into the mechanism by which CAPE 
interferes with signaling cascades initiated upon stimulation of VSMC with 
PDGF-BB. It is noteworthy that we provided evidence that HO-1 does not 
contribute to the anti-proliferative property of CAPE whereas caveolin-1 is up 
regulated in a p38-dependant manner. Consistent with previous studies 
(Peterson et al., 2003; Kim et al., 2005; Peterson et al., 1999), caveolin-1 
appears to be important in proliferative signaling in VMSC, and may, therefore, 
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be considered as a target for new therapeutic approaches to overcome 
neointimal remodeling and restenosis. 
O
O
OH
OH
CAPE
 
p3P
p38 M
? 
Figure 3
and a su
 
 
c-GMP 8
G1
S
G2
M
?
?
APK Caveolin-1
 
4. CAPE inhibits VSMC proliferation via a HO-1-independent activation of p38 MAPK 
bsequent increased expression of caveolin-1 in a p38 MAPK-dependent manner.  
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G APPENDIX 
1 Abbreviations 
7-AAD 7-amino-actinomycin D 
ACE  angiotensin-converting enzyme 
AG AG 1478 
Ang II angiotensin II 
AP-1 activating protein 1 
APS ammonium persulfate 
Aph aphidicolin 
AT1/2-R angiotensin II type 1/2 receptor 
bFGF  basic fibroblast growth factor 
BrdU bromodeoxyuridine 
BSA bovine serum albumine 
C Celsius 
CAPE caffeic acid phenethyl ester 
Cav-1 caveolin-1 
CBP CREB binding protein 
Cdk cyclin-dependent kinase 
Co control 
CREB cAMP-response-element binding protein 
CS calf serum 
DNA deoxyribonucleic acid 
DAG diacylglycerol 
DMEM Dulbecco’s Modified Eagle’s medium 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
EGF epidermal growth factor 
EGF-R epidermal growth factor receptor 
EGTA ethylene glycol–bis(2-aminoethyl ether) 
tetraacetic acid 
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eIF2B eukaryotic initiation factor 2B 
Erk 1/2 extracellular-signal regulated kinase 1/2 
FOXO FOXO family of Forkhead transcription factors 
GPCR G-protein coupled receptor 
Gab 1 Grb 2-associated binder 1 
Grb 2 growth factor receptor bound protein 2 
GSK 3  glycogen synthase kinase 3 
Gy  Gray 
h  hour 
HB  heparin-binding 
IL 6  interleukin 6 
IP3  inositol trisphosphate 
JNK c-Jun N-terminal kinase 
LDL low density lipoprotein 
MAPK mitogen activated protein kinase 
MCP-1 monocyte chemoattractant protein 1 
m  milli 
M  molar 
Mdm2  mouse double minute 2 
min  minutes 
MKK (MEK) MAPK kinase 
MKKK  MAPK kinase kinase 
mTor  mammalian target of rapamycin 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
mRNA messenger RNA 
n  nano 
NAC  N-Acetyl-L-Cysteine 
NAD(P)H  nicotinamide adenine dinucleotide (phosphate) 
NFκB  nuclear factor κB 
NO  nitric oxide 
NOS  nitric oxide synthase 
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oxLDL oxidised LDL 
p phospho 
PAA polyacrylamide 
PBS phosphate-buffered saline 
PCNA proliferating cell nuclear antigen 
PDGF platelet-derived growth factor 
PDK 1 3-phosphoinositide-dependent kinase I 
PH pleckstrin homology 
PI propidium iodide 
PI3-k phosphoinositide-3 kinase 
PKA/B/C/G  protein kinase A/B/C/G 
PLC  phospholipase C 
PMSF phenylmethylsulfonyl fluoride 
Poly[dIdC] Polydesoxyinosine-desoxycytosine 
Ppm parts per million 
PP2A protein phosphatase 2A 
PtdIns phosphatidylinsositol 
PTEN phosphatase and tensin homologue deleted 
from chromosome 10 
PYK 2 proline rich tyrosine kinase 2 
R restriction point 
Rb Retinoblastoma protein 
RNA ribonucleic acid 
ROS reactive oxygen species 
RV resveratrol 
S, Ser serine 
SDS sodium dodecyl sulphate 
SEM Standard error of the mean value 
SH1/2 Src homology 1/2 
Shc Src-homology 2 domain containing 
SHIP Src-homology 2-containing inositol 
phosphatase 
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Shp-2 Src-homology 2-containing phosphatase-2 
Sos  son of sevenless 
T, Thr threonine 
TAE Tris, acetate, EDTA buffer 
TBE Tris, borate, EDTA buffer with Triton X-100 
TBS-T Tris buffered saline solution with Tween 
TEMED N,N,N´,N´-tetramethylethylenediamine 
TGF-β transforming growth factor β 
TRIS Tris(hydroxymethyl)-aminomethane 
v volume 
VSMC vascular smooth muscle cell 
w  weight 
WM wortmannin 
Y, Tyr tyrosine 
µ micro 
 
2 Alphabetical order of companies 
Amersham Pharmacia Freiburg, Germany 
Beckman Instruments Munich, Germany 
BD biosciences Heidelberg, Germany 
Biochrom Berlin, Germany 
BioRad Laboratories Munich, Germany 
BioSource Nivelle, Belgium 
Calbiochem Schwalbach, Germany 
Charles River GmbH Sulzfeld, Germany 
Cell Signaling Frankfurt, Germany 
Eppendorf Maintal, Germany 
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Invitrogen Karlsruhe, Germany 
Jackson ImmunoResearch West Grove, USA 
Millipore Eschborn, Germany 
NEN  Cologne, Germany 
Pan Biotech Aidenbach, Germany 
Qbiogene-Alexis Grünberg, Germany 
PAA Laboratories  Linz, Austria 
PAN Aidenbach, Germany 
Peske  Aindling-Pichl, Germany 
PharMingen  San Diego, CA, USA 
Promega  Heidelberg, Germany 
Roche Mannheim, Germany 
Roth Karlsruhe, Germany 
Serotec Eching, Germany 
Sigma-Aldrich Taufkirchen, Germany 
Shimadzu Duisburg, Germany 
Tecan  Crailsheim, Germany 
Tocris Ellisville, USA 
Upstate Biotechnology  Lake Placid, USA 
Zeiss Oberkochen, Germany 
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3 Publications 
3.1 Abstracts 
T.U. Roos, U.G.B. Haider, A.M. Vollmar, V.M. Dirsch. 
Resveratrol impairs angiotensin II-mediated Akt activation in vascular smooth 
muscle cells by affecting the phosphotyrosine phosphatase Shp-2. 
Naunyn Schmiedebergs Arch Pharmacol. 2005 Feb;371(Supp. 1):R15 
3.2 Original publications 
Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, 
Vollmar AM, Dirsch VM. 
Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt 
activation: role of Gab1 and Shp-2 
Mol Pharmacol. 2005 Jul;68(1):41-8 
 
Thomas U. Roos, Andrea Schwaiberger, Angelika M. Vollmar, Verena M. 
Dirsch. 
p38 mitogen-activated protein kinase-mediated induction of caveolin-1 
contributes to the antiproliferative effect of caffeic acid phenethyl ester in rat 
aortic vascular smooth muscle cells 
Manuscript in preparation 
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